Podcasts about nature aging

I did it! I took a chance, followed my gut, and launched something brand new. I told myself what I always tell you guys…Risk It! or Regret It! Introducing my brand-new short-form syndicated radio feature: “Keeping the ‘Live' in Alive! with Debbie Nigro” Proudly sponsored by NativePath Collagen — the stuff that's got me hiking again, baby! For the past 6 months, I've been secretly developing this new ‘thing''. Figuring out what it should be, how it should sound, and who would be open enough to collaborate with me.   Why this, why now? Lately, I've found myself diving into wellness like never before. Not just for fun (though some of it is hilarious), but because my biological clock feels more like a ticking time bomb these days. I'm trying to maximize my remaining time on this planet as are many other people I know. I'm constantly researching and talking about mental wellness, physical wellness, nutrition, longevity, and all the weird and wonderful science behind staying vibrant and ALIVE. And sharing it all on my “Wellness Wednesday” segments of The Debbie Nigro Show just wasn't enough anymore. So, I created this new feature — fast-moving, funny, and full of fascinating wellness info — to syndicate nationwide. AND I'm testing it out in real time.    The Launch

Biophilia was coined from a theory of the biologist, E. O. Wilson, who stated that human beings have an innate and even genetically determined affinity to nature. In other words, it is important that this connection is kept to facilitate wellness. In this episode, Dr. Vanessa Champion, editor and founder of The Journal of Biophilic Design, joins Lori to review initiatives which can be taken in senior living environments in response to this very human need... and why these interventions are necessary. For links to resources related to this episode - there are a lot this month! - please visit us at thirdage.design/s5e02 - and while you're there, hit the Join Us button! We'll show our thanks for your interest by sending you our periodic, exclusive - and free! - TAD Extra.

Die Themen in den Wissensnachrichten: +++ Omega-3-Fettsäuren könnten Altersveränderungen bremsen +++ Altsteinzeit-Menschen hatten wohl schon Piercings +++ Koffein schützt vermutlich Mate-Pflanze +++**********Weiterführende Quellen zu dieser Folge:Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial, Nature Aging, 03.02.2025Probable Use of Labrets Among the Mid Upper Paleolithic Pavlovian Peoples of Central Europe, Journal of Paleolithic Archaeology, 23.01.2025Yerba mate (Ilex paraguariensis) genome provides new insights into convergent evolution of caffeine biosynthesis, Elife, 08.01.2025Bioaccumulation of microplastics in decedent human brains, Nature Medicine, 03.02.2025Local chemical heterogeneity enabled superior zero thermal expansion in nonstoichiometric pyrochlore magnets, National Science Review, 17.12.2024Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok auf&ab , TikTok wie_geht und Instagram .

Une étude récente publiée dans Nature Aging par des chercheurs de l'Université de Washington a mis en lumière le rôle crucial des cellules immunitaires du cerveau, appelées microglies, dans le développement de la maladie d'Alzheimer. Traditionnellement considérées comme les gardiennes du système nerveux central, les microglies jouent un rôle essentiel dans la surveillance et la protection du cerveau. Cependant, cette étude révèle que, dans certaines conditions, ces cellules peuvent contribuer à la progression de la neurodégénérescence.Les microglies sont des cellules immunitaires résidant dans le cerveau, capables de détecter et de répondre rapidement aux anomalies, telles que les dépôts de protéines bêta-amyloïdes caractéristiques de la maladie d'Alzheimer. En temps normal, elles phagocytent ces dépôts pour protéger les neurones. Toutefois, l'étude de l'Université de Washington a découvert qu'une sous-population de microglies, lorsqu'elle est suractivée par le stress lié au processus dégénératif, libère des lipides toxiques qui aggravent la neurodégénérescence. Cette suractivation entraîne une réponse inflammatoire excessive, contribuant à la progression de la maladie.Les chercheurs ont observé ce phénomène chez des modèles murins atteints de la maladie d'Alzheimer. Ils ont également identifié la présence de ces microglies suractivées dans le tissu cérébral de personnes décédées avec la maladie. Ces découvertes suggèrent que, bien que les microglies aient un rôle protecteur initial, leur suractivation peut devenir délétère, exacerbant les dommages neuronaux.Cette étude souligne l'importance de réguler l'activité microgliale pour prévenir ou ralentir la progression de la maladie d'Alzheimer. Des approches thérapeutiques visant à moduler la réponse des microglies pourraient offrir de nouvelles perspectives dans le traitement de cette pathologie neurodégénérative. Par exemple, des stratégies visant à réduire la libération de lipides toxiques par les microglies suractivées ou à inhiber leur suractivation pourraient être explorées.En conclusion, les microglies jouent un rôle double dans la maladie d'Alzheimer : protectrices en phase initiale, elles peuvent devenir nuisibles lorsqu'elles sont suractivées. Comprendre les mécanismes qui régulent cette transition est essentiel pour développer des interventions thérapeutiques efficaces. Les travaux de l'Université de Washington apportent une contribution significative à cette compréhension, ouvrant la voie à de nouvelles recherches sur le rôle des cellules immunitaires du cerveau dans les maladies neurodégénératives. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Milyen kütyüt vegyünk karácsonyra? Tudás.hu     2024-12-10 05:25:59     Infotech Karácsonyi vásár Kütyü Zajlik a karácsonyi vadászidény, úgyhogy tömegek indulnak bevásárolni. Kedvező körülmény, hogy az árudiverzitás óriási: soha nem lehetett kapni ennyiféle dolgot. Nem lesz haszontalan tehát áttekinteni, hogy mit vásároljunk ebben az évben karácsonyra. Ebben a végtelen sokféleségben az ún. "infotainment" szegmensre fogunk koncentrálni: a szakkifejezé Ebben korban öregszik leginkább az emberi agy 24.hu     2024-12-10 09:46:37     Tudomány A Nature Aging szaklapban megjelent kutatás szerint 13 kulcsfontosságú fehérje határozza meg az agy öregedését. Vége a harmadik szintre lépett az LG Mínuszos     2024-12-10 10:33:14     Infotech Kiberbiztonság Az LG Electronics (LG) harmadik szintű CSMS tanúsítványt szerzett, ami a vállalat innovatív mobilitási megoldásainak digitális biztonságát tanusítja. Az LG a közelmúltban megszerezte a globális tesztelő és tanúsító ügynökség, a TÜV Rheinland 3. szintű bizonyítványát kiberbiztonsági irányítási rendszerére (CSMS) vonatkozóan. Ez a kategóriában elérhe Az MI nagyobb arányban szűri ki a mellrákos eseteket, állítja egy tanulmány ITBusiness     2024-12-10 04:14:35     Infotech USA Mellrák Az Észak-Amerikai Radiológiai Társaság (RSNA) idei éves találkozóján a kutatók bejelentették: azoknál a nőknél, akik hajlandóak voltak plusz összeget fizetni az MI-vel támogatott mellrákszűrésért, 21 százalékkal nagyobb valószínűséggel fedezték fel a rákot. Ezt az eredményt az éves konferencián ismertették, és az RSNA hivatalos közleményében is rés Tudományos függetlenség vagy központosítás? Újra átalakítják a HUN-REN Magyar Kutatási Hálózatot Telex     2024-12-10 13:43:26     Tudomány Az első terv heves ellenállást váltott ki a kutatókból. A javaslatokat még mindig gyúrják, a kutatóközpontok főigazgatói és a politikai szereplők akarata közeledik egymáshoz, de sokan még mindig a totális központosítástól és a tudományos függetlenség elvesztésétől tartanak. Digitális ugródeszka a kisvállalkozásoknak – itt a Demján Sándor Program! ICT Global     2024-12-10 10:49:23     Infotech KKV Webáruház Demján Sándor Sok kisvállalkozás álma, hogy erősebb online jelenléttel törjön be az e-kereskedelem világába. Most végre itt a lehetőség: a Demján Sándor Program keretében a magyar mikro- és kisvállalkozások számára egyedi támogatást kínál a kormány. Hangfelvételekből készít pontos utcaképeket a mesterséges intelligencia Bitport     2024-12-10 08:01:00     Infotech Mesterséges intelligencia Hangfelvétel Segíthet megérteni azt az eddig kevéssé kutatott jelenséget, ahogy az emberek egyszerre több érzékszervükön keresztül szereznek benyomásokat a környezetükről, például hangok alapján is élesen maguk elé tudnak képzelni konkrét helyeket. Egy karibi sziget az MI nagy nyertese First Class     2024-12-10 10:39:14     Infotech Mesterséges intelligencia A karibi térségben fekvő Anguilla úgy tesz zsebre komoly összegeket a mesterséges intelligenciának köszönhetően, hogy ők nem is végeznek ilyen fejlesztéseket. Karácsonykor legtöbben gyermekek javára terveznek adományozni Márkamonitor     2024-12-10 07:36:03     Mobiltech Ajándék Adomány Yettel A Yettel idén már ötödik alkalommal mérte fel a magyarok karácsonyi szokásait a kapcsolattartástól az ajándékozáson keresztül az adományozásig. Utóbbival kapcsolatban többek közt megvizsgálták, hogy terveznek-e adományozni a megkérdezettek, és ha igen, kiket, mivel és milyen összeggel támogatnak majd.   A válaszadók háromnegyede általában szokott a Klaviatúrába integrálva is elérhető a Raspberry Pi 5 HWSW     2024-12-10 12:50:08     Infotech Raspberry Pi A Raspberry Pi 500 névre hallgató eszközzel a cég kompakt asztali PC-t kínál, a legfrissebb Raspberry Pi felturbózott verziójával a motorháztető alatt. Titkos nukleáris várost találtak a jég alatt, ha elolvad, a sugárzás rászabadul a világra Promotions     2024-12-10 03:54:00     Tudomány Világűr NASA A NASA tudósai aggódnak a most is sugárzó, nukleáris jég alatti város miatt. Magyar milliárdos is elkísérte Floridába Orbánt Forbes     2024-12-10 08:22:15     Cégvilág Orbán Viktor Donald Trump Elon Musk Florida Hétfő délután a floridai Mar-a-Lagóban Orbán Viktor miniszterelnök tárgyalást folytatott Donald Trumppal, Elon Muskkal és Michael Waltzcal. Google NotebookLM: A kisvállalkozások új szupereszköze Minner     2024-12-10 07:00:00     Infotech Mesterséges intelligencia Google KKV Mi lenne, ha vállalkozásunk főbb adatait és dokumentumait egy helyen tárolhatnánk, ahol azok azonnal hozzáférhetők, kereshetők és elemezhetők egy intelligens, mesterséges intelligencia alapú platformon keresztül? A Google NotebookLM pontosan ezt kínálja. Eredetileg kutatóknak és egyéni felhasználóknak készült, de mára egy üzleti szupereszközzé vált A további adásainkat keresd a podcast.hirstart.hu oldalunkon.

Milyen kütyüt vegyünk karácsonyra? Tudás.hu     2024-12-10 05:25:59     Infotech Karácsonyi vásár Kütyü Zajlik a karácsonyi vadászidény, úgyhogy tömegek indulnak bevásárolni. Kedvező körülmény, hogy az árudiverzitás óriási: soha nem lehetett kapni ennyiféle dolgot. Nem lesz haszontalan tehát áttekinteni, hogy mit vásároljunk ebben az évben karácsonyra. Ebben a végtelen sokféleségben az ún. "infotainment" szegmensre fogunk koncentrálni: a szakkifejezé Ebben korban öregszik leginkább az emberi agy 24.hu     2024-12-10 09:46:37     Tudomány A Nature Aging szaklapban megjelent kutatás szerint 13 kulcsfontosságú fehérje határozza meg az agy öregedését. Vége a harmadik szintre lépett az LG Mínuszos     2024-12-10 10:33:14     Infotech Kiberbiztonság Az LG Electronics (LG) harmadik szintű CSMS tanúsítványt szerzett, ami a vállalat innovatív mobilitási megoldásainak digitális biztonságát tanusítja. Az LG a közelmúltban megszerezte a globális tesztelő és tanúsító ügynökség, a TÜV Rheinland 3. szintű bizonyítványát kiberbiztonsági irányítási rendszerére (CSMS) vonatkozóan. Ez a kategóriában elérhe Az MI nagyobb arányban szűri ki a mellrákos eseteket, állítja egy tanulmány ITBusiness     2024-12-10 04:14:35     Infotech USA Mellrák Az Észak-Amerikai Radiológiai Társaság (RSNA) idei éves találkozóján a kutatók bejelentették: azoknál a nőknél, akik hajlandóak voltak plusz összeget fizetni az MI-vel támogatott mellrákszűrésért, 21 százalékkal nagyobb valószínűséggel fedezték fel a rákot. Ezt az eredményt az éves konferencián ismertették, és az RSNA hivatalos közleményében is rés Tudományos függetlenség vagy központosítás? Újra átalakítják a HUN-REN Magyar Kutatási Hálózatot Telex     2024-12-10 13:43:26     Tudomány Az első terv heves ellenállást váltott ki a kutatókból. A javaslatokat még mindig gyúrják, a kutatóközpontok főigazgatói és a politikai szereplők akarata közeledik egymáshoz, de sokan még mindig a totális központosítástól és a tudományos függetlenség elvesztésétől tartanak. Digitális ugródeszka a kisvállalkozásoknak – itt a Demján Sándor Program! ICT Global     2024-12-10 10:49:23     Infotech KKV Webáruház Demján Sándor Sok kisvállalkozás álma, hogy erősebb online jelenléttel törjön be az e-kereskedelem világába. Most végre itt a lehetőség: a Demján Sándor Program keretében a magyar mikro- és kisvállalkozások számára egyedi támogatást kínál a kormány. Hangfelvételekből készít pontos utcaképeket a mesterséges intelligencia Bitport     2024-12-10 08:01:00     Infotech Mesterséges intelligencia Hangfelvétel Segíthet megérteni azt az eddig kevéssé kutatott jelenséget, ahogy az emberek egyszerre több érzékszervükön keresztül szereznek benyomásokat a környezetükről, például hangok alapján is élesen maguk elé tudnak képzelni konkrét helyeket. Egy karibi sziget az MI nagy nyertese First Class     2024-12-10 10:39:14     Infotech Mesterséges intelligencia A karibi térségben fekvő Anguilla úgy tesz zsebre komoly összegeket a mesterséges intelligenciának köszönhetően, hogy ők nem is végeznek ilyen fejlesztéseket. Karácsonykor legtöbben gyermekek javára terveznek adományozni Márkamonitor     2024-12-10 07:36:03     Mobiltech Ajándék Adomány Yettel A Yettel idén már ötödik alkalommal mérte fel a magyarok karácsonyi szokásait a kapcsolattartástól az ajándékozáson keresztül az adományozásig. Utóbbival kapcsolatban többek közt megvizsgálták, hogy terveznek-e adományozni a megkérdezettek, és ha igen, kiket, mivel és milyen összeggel támogatnak majd.   A válaszadók háromnegyede általában szokott a Klaviatúrába integrálva is elérhető a Raspberry Pi 5 HWSW     2024-12-10 12:50:08     Infotech Raspberry Pi A Raspberry Pi 500 névre hallgató eszközzel a cég kompakt asztali PC-t kínál, a legfrissebb Raspberry Pi felturbózott verziójával a motorháztető alatt. Titkos nukleáris várost találtak a jég alatt, ha elolvad, a sugárzás rászabadul a világra Promotions     2024-12-10 03:54:00     Tudomány Világűr NASA A NASA tudósai aggódnak a most is sugárzó, nukleáris jég alatti város miatt. Magyar milliárdos is elkísérte Floridába Orbánt Forbes     2024-12-10 08:22:15     Cégvilág Orbán Viktor Donald Trump Elon Musk Florida Hétfő délután a floridai Mar-a-Lagóban Orbán Viktor miniszterelnök tárgyalást folytatott Donald Trumppal, Elon Muskkal és Michael Waltzcal. Google NotebookLM: A kisvállalkozások új szupereszköze Minner     2024-12-10 07:00:00     Infotech Mesterséges intelligencia Google KKV Mi lenne, ha vállalkozásunk főbb adatait és dokumentumait egy helyen tárolhatnánk, ahol azok azonnal hozzáférhetők, kereshetők és elemezhetők egy intelligens, mesterséges intelligencia alapú platformon keresztül? A Google NotebookLM pontosan ezt kínálja. Eredetileg kutatóknak és egyéni felhasználóknak készült, de mára egy üzleti szupereszközzé vált A további adásainkat keresd a podcast.hirstart.hu oldalunkon.

What the dinosaurs left behind tells the story of their rise to dominanceBones aren't the only thing we can use to understand the dinosaurs. A new study of a rich trove of fossilized feces and vomit is telling the story of how dinosaurs diversified and came to dominate the planet starting 230 million years ago. Paleontologist Martin Qvarnström from Uppsala University in Sweden said it appears that the secret to dinosaurs' success is in their ability to adapt to their changing environment. Their research is published in the journal Nature. A new kind of ‘walking' shorts could help with mobilityScientists have incorporated artificial tendons and electric motors into shorts to provide support and assistance to the hip flexor muscles that are critical for walking. In both young and old people the shorts improved performance and so could make a difference for those whose mobility has been compromised. Enrica Tricomi, a visiting researcher at the Technical University of Munich, co-developed this prototype. The study was published in the journal Nature.Shining a bright light on a new way to discourage shark attacksSharks attacks on humans are often a result of mistaken identity, when they mistake a swimming human or a surfboard for a seal or sea lion. Researchers have found that a bright patterns of LED lights can break up the visual pattern of a swimmer so that they look less like a shark's usual prey. Dr. Lucille Chapuis was part of the team that tested various patterns of lights in Seal Island, South Africa. Their research was published in Current Biology.Different species of humans walked side-by-side in Africa millions of years agoPreserved footprints near a lakeshore in Kenya show that two species of early humans, Homo erectus and Paranthropus boisei, shared the same watering hole 1.5 million years ago. This is the first direct evidence of two species of hominids sharing the same space at the same time.Dr. Kevin Hatala, professor of Biology at Chatham University, and his team's findings are in the journal Science. We no longer know how to make humans live longer – only betterHuman lifespan lengthened amazingly in the 20th century, thanks to reductions in infant mortality, improvements in public health, and successes against infectious disease. But according to a new study by S. Jay Olshansky, those gains have started to flatline in recent years. By looking at the countries with the longest lifespans, Olshansky and his colleagues found that we have traded childhood diseases for age-related diseases like cancers and Alzheimer's, and so we shouldn't expect to make many more gains in human lifespan using our current methods. Instead, he says, we should focus on improving the quality of the extra years we've gained so far. His work was published in the journal Nature Aging.We also speak with William Mair, a Professor of Molecular Metabolism at the Harvard School of Public Health. He is part of a new field of study called Geroscience, which looks at slowing down the process of aging as a whole. In his lab he has been able to extend the lifespan of simpler creatures like nematode worms and mice, and says while we have no proof we can extend a human's maximum lifespan at this time, that doesn't mean it won't be possible in the future. 

Uno studio pubblicato di recente sulla rivista Nature Aging sottolinea quanto sia positivo, soprattutto per il nostro cervello, allenarsi anche solo durante il fine settimana. Ma come farlo nel modo corretto? Ci aiuta a pianificare l’allenamento del weekend Elena Casiraghi, docente di metodologia dello sport all'Università di Pavia e specialista in nutrizione e integrazione dello sport.

Humanity is hitting the upper limit of life expectancy, according to a new study. Advances in medical technology and genetic research—not to mention larger numbers of people making it to age 100—are not translating into marked jumps in lifespan overall, according to researchers who found shrinking longevity increases in countries with the longest-living populations. “We have to recognize there's a limit” and perhaps reassess assumptions about when people should retire and how much money they'll need to live out their lives, said S. Jay Olshansky, a University of Illinois-Chicago researcher who was lead author of the study published by the journal Nature Aging. “We are reaching a plateau” in life expectancy, he agreed. It's always possible some breakthrough could push survival to greater heights, “but we don't have that now,” said Mark Hayward, a University of Texas researcher. Life expectancy is one of the world's most important health measures, but it is also imperfect: It is a snapshot estimate that cannot account for deadly pandemics, miracle cures, or other unforeseen developments that might kill or save millions of people. In the new research, Olshansky and his research partners tracked life expectancy estimates for the years 1990 to 2019, drawn from a database administered by the Max Planck Institute for Demographic Research. The researchers focused on eight of the places in the world where people live the longest—Australia, France, Hong Kong, Italy, Japan, South Korea, Spain, and Switzerland. The study suggests that there's a limit to how long most people live, and we've about hit it, Olshansky said. “We're squeezing less and less life out of these life-extending technologies. And the reason is, aging gets in the way,” he said. It may seem common to hear of a person living to 100. In 2019, a little over 2% of Americans made it to 100, compared with about 5% in Japan and 9% in Hong Kong, Olshansky said. It's likely that the ranks of centenarians will grow in the decades ahead, experts say, but that's because of population growth. The percentage of people hitting 100 will remain limited, likely with fewer than 15% of women and 5% of men making it that long in most countries, Olshansky said. This article was provided by The Associated Press.

In today's world, where anti-aging products and longevity hacks are all the rage, the idea of radically extending human life has caught some serious momentum. You've probably heard it before—predictions about living to 150, maybe even 200. But a recent study published in Nature Aging on October 7, 2024, throws a cold splash of reality on this idea. Titled Implausibility of Radical Life Extension in Humans in the Twenty-First Century, this research suggests we may be approaching a natural limit to how long humans can actually live.  

A new study says humanity is hitting the upper limit of life expectancy. 一项新的研究表明，人类正在达到预期寿命的上限。 Developments in medical technology and genetic research are not leading to major increases in lifespan overall, the researchers said. 研究人员表示，医疗技术和基因研究的发展并没有导致整体寿命的大幅延长。 The study was published recently in Nature Aging. 该研究最近发表在《自然衰老》杂志上。 “We have to recognize there's a limit” and possibly change ideas about when people should retire and how much money they will need to live out their lives, said S. Jay Olshansky of the University of Illinois-Chicago. Olshansky was the lead writer of the study. 伊利诺伊大学芝加哥分校的 S. Jay Olshansky 表示，“我们必须认识到这是有限制的”，并可能改变人们关于何时退休以及需要多少钱来度过余生的想法。奥尔尚斯基是这项研究的主要作者。 Mark Hayward of the University of Texas was not involved in the study. However, he called it “a valuable addition to the mortality literature.” 德克萨斯大学的马克·海沃德没有参与这项研究。然而，他称其为“对死亡率文献的宝贵补充”。 “We are reaching a plateau” in life expectancy, he said. 他说，预期寿命“我们正在达到一个平台期”。 It is always possible that some new development could push survival to greater lengths, “but we don't have that now,” Hayward said. 海沃德说，一些新的发展总是有可能将生存推向更大的长度，“但我们现在还没有这样的能力”。Life expectancy is an estimate of the average number of years a baby born in a particular year might expect to live. The measurement assumes death rates at the time of birth do not change. 预期寿命是对特定年份出生的婴儿预期寿命的平均年数的估计。该测量假设出生时的死亡率没有变化。 Life expectancy is one of the world's most important health measures. Still the life expectancy measurement has problems. For example, life expectancy is an estimate that cannot include new developments or changes that might affect the length of people's lives. 预期寿命是世界上最重要的健康指标之一。预期寿命的测量仍然存在问题。例如，预期寿命是一种估计值，不能包括可能影响人们寿命长度的新发展或变化。 These unknown developments could include pandemics or new treatments for diseases. 这些未知的发展可能包括流行病或疾病的新疗法。 In the recent study, Olshansky and other researchers followed life expectancy estimates for the years 1990 to 2019. They took information from a database administered by the Max Planck Institute for Demographic Research. 在最近的研究中，奥尔尚斯基和其他研究人员跟踪了 1990 年至 2019 年的预期寿命估计。他们从马克斯·普朗克人口研究所管理的数据库中获取信息。 The researchers paid special attention to eight of the places in the world where people live the longest: Australia, France, Hong Kong, Italy, Japan, South Korea, Spain and Switzerland.研究人员特别关注了世界上人们寿命最长的八个地方：澳大利亚、法国、香港、意大利、日本、韩国、西班牙和瑞士。 The United States does not rank in the top 40, but it was included in the study because the researchers live in the U.S. Also, some experts have made estimates that life expectancy in the U.S. would increase greatly in the 2000s, Olshansky said. 奥尔尚斯基表示，美国并未进入前40名，但由于研究人员居住在美国，因此被纳入研究范围。此外，一些专家估计，美国的预期寿命将在2000年代大幅增加。Women continue to live longer than men. Female life expectancy improvements are still happening — but at a slower rate, the researchers found. In 1990, the average amount of improvement was about 2.5 years every 10 years. In the 2010s, it was 1.5 years — but almost zero in the United States. 女性的寿命仍然比男性长。研究人员发现，女性预期寿命仍在延长，但速度较慢。1990年，平均每10年改善2.5年左右。2010 年代，这个数字是 1.5 年——但在美国几乎为零。 Life expectancy measurements in the U.S. are more difficult. The country is affected by a number of causes of early death. Examples include drug overdoses, shootings, weight problems and uneven health care services. 美国的预期寿命测量更加困难。该国受到多种早逝原因的影响。例子包括药物过量、枪击、体重问题和医疗保健服务不均衡。But in one calculation, the researchers estimated what would happen in all nine places if all deaths before age 50 were prevented. The increase at best was still only 1.5 years, Olshansky said. 但在一项计算中，研究人员估计了如果 50 岁之前的所有死亡都被避免的话，所有九个地方将会发生什么。奥尔尚斯基说，最好的情况是增加了 1.5 年。 The study suggests that there is a limit to how long most people live, and we have almost hit it, Olshansky said. 奥尔尚斯基说，这项研究表明，大多数人的寿命是有极限的，而我们几乎已经达到了极限。 “We're squeezing less and less life out of these life-extending technologies. And the reason is, aging gets in the way,” he said. “我们从这些延长生命的技术中榨取的生命越来越少。原因是，衰老会成为障碍，”他说。 It may seem common to hear of a person living to 100. Former U.S. President Jimmy Carter, for example, recently celebrated his 100th birthday. 听说有人活到 100 岁似乎很常见。例如，美国前总统吉米·卡特 (Jimmy Carter) 最近庆祝了他的 100 岁生日。 In 2019, a little over two percent of Americans made it to 100, compared to about five percent in Japan and nine percent in Hong Kong, Olshansky said. 奥尔尚斯基说，2019 年，略高于 2% 的美国人达到了 100 岁，而日本和香港的这一比例约为 5% 和 9%。 It is likely that the number of people who reach 100 will grow in the years ahead, experts say, but that is because of population growth. The percentage of people hitting 100 will remain limited, likely with fewer than 15 percent of women and 5 percent of men making it that long in most countries, Olshansky said. 专家表示，未来几年，活到 100 岁的人数可能会增加，但这是因为人口增长。奥尔尚斯基表示，活到 100 岁的人口比例仍然有限，在大多数国家，能活到 100 岁的女性和男性可能只有不到 15% 和 5%。

Subscribe to our channel: https://www.youtube.com/@optispan How much longer might humans live? This question has fascinated scientists, philosophers, and dreamers for centuries. The average human lifespan has already increased dramatically over the past hundred years thanks to advances in medicine, public health, and technology, and the prospect of radically extending human life remains one of humanity's most compelling frontiers. A recent paper published in the scientific journal Nature Aging argues that radical life extension is unlikely to happen in the 21st century. The paper has sparked fascinating conversation in the longevity industry around topics such as realistic deliverables for the field, the predictive value of past technological trajectories, the reasons behind lifespan decreases in the western world, incremental versus bold research goals, and where we should go from here. Matt and Nick discuss the paper and provide their own take on the prospect of radical life extension and what we can realistically expect to see in the coming decades. Producers: Tara Mei, Nicholas Arapis Video Editor: Jacob Keliikoa DISCLAIMER: The information provided on the Optispan podcast is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find us: Twitter: https://twitter.com/optispanpodcast Twitter: https://twitter.com/optispan Twitter: https://twitter.com/mkaeberlein Linkedin: https://www.linkedin.com/company/optispan Instagram: https://www.instagram.com/optispanpodcast/ TikTok: https://www.tiktok.com/@optispan https://www.optispan.life/ Hi, I'm Matt Kaeberlein. I spent the first few decades of my career doing scientific research into the biology of aging, trying to understand the finer details of how humans age in order to facilitate translational interventions that promote healthspan and improve quality of life. Now I want to take some of that knowledge out of the lab and into the hands of people who can really use it. On this podcast I talk about all things aging and healthspan, from supplements and nutrition to the latest discoveries in longevity research. My goal is to lift the veil on the geroscience and longevity world and help you apply what we know to your own personal health trajectory. I care about quality science and will always be honest about what I don't know. I hope you'll find these episodes helpful!

Theo một nghiên cứu của giáo sư S. Jay Olshansky thuộc đại học Illinois ở Chicago, được đăng trên tạp chí Nature Aging thì con người có một giới hạn về tuổi thọ, đó là ước tính về số năm trung bình mà một đứa trẻ sinh ra có thể mong đợi sống được.

Willkommen zum wöchentlichen Longevity Briefing! Jede Woche sprechen wir über die neuesten Entwicklungen in der Welt der Healthy Longevity. Wir bringen dir wissenschaftlich fundierte News, neue Therapien, spannende Forschungsergebnisse und vieles mehr.Diese Woche: 1. Werden wir bald alle 90, 100, 120? Mitnichten! Eine gerade in NATURE AGING veröffentlichte Studie dazu schlägt gerade hohe Wellen in derLanglebigkeits-Szene. Zum Blogartikel: https://stayoung.de/blog/radikale-lebensverlaengerung-unwahrscheinlich Zur Studie: https://pubmed.ncbi.nlm.nih.gov/39375565/ 2. US-Forscher entwickeln Bluttest zur besseren Vorhersage von schweren Lungenerkrankungen Zum Blogartikel: https://stayoung.de/blog/Bluttest-zur-Vorhersage-von-Lungenerkrankungen Zur Studie: https://www.atsjournals.org/doi/10.1164/rccm.202403-0613OC 3. Der Grönlandhai und sein Geheimnis der Langlebigkeit Zum Blogartikel: https://stayoung.de/blog/groenlandhai Zur Studie: ⁠https://www.biorxiv.org/content/10.1101/2024.09.09.611499v1⁠ Bonus-Tipp:Melde dich jetzt kostenlos zu unserem Longevity Briefing als Newsletter an und erhalte den kostenlosen Ratgeber zur Hormonersatztherapie: https://link.stayoung.de/Ratgeber-HET

In this episode, Lauren and Matt talk with Leah Richmond-Rakerd, PhD who is an Assistant Professor in the Department of Psychology at the University of Michigan. Her research focuses on emotional and behavioral dysregulation across the life course. Here, Dr. Richmond-Rakerd will discuss her recent study on “The Associations of Hospital-Treated Infections with Subsequent Dementia: Nationwide 30-year Analysis” that was published in Nature Aging. Articles Discussed in Episode: Richmond-Rakerd LS, Iyer MT, D'Souza S, Khalifeh L, Caspi A, Moffitt TE, Milne BJ. Associations of hospital-treated infections with subsequent dementia: nationwide 30-year analysis. Nat Aging. 2024 Jun;4(6):783-790. doi: 10.1038/s43587-024-00621-3. Epub 2024 May 7. PMID: 38714911. Milne BJ, Atkinson J, Blakely T, Day H, Douwes J, Gibb S, Nicolson M, Shackleton N, Sporle A, Teng A. Data Resource Profile: The New Zealand Integrated Data Infrastructure (IDI). Int J Epidemiol. 2019 Jun 1;48(3):677-677e. doi: 10.1093/ije/dyz014. Erratum in: Int J Epidemiol. 2019 Jun 1;48(3):1027. doi: 10.1093/ije/dyz054. PMID: 30793742. NZ Integrated Data Infrastructure: https://www.stats.govt.nz/integrated-data/integrated-data-infrastructure/ Visit the Center to Accelerate Population Research in Alzheimer's (CAPRA) website to learn more. The transcript for this episode can be found here.You can subscribe to Minding Memory on Apple Podcasts, Spotify, or wherever you listen to podcasts. Hosted on Acast. See acast.com/privacy for more information.

Die Themen in den Wissensnachrichten: +++ Kolumbus kein Italiener, sondern Spanier? +++ Gewinner des Wirtschaftsnobelpreises erklären Wohlstand +++ Steigerung der Lebenserwartung lässt nach +++**********Weiterführende Quellen zu dieser Folge:Cristóbal Colon fue judío y de esta zona de España. Mira el documental 'Colón ADN, su verdadero origen', rtve, 13/10/2024The Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel, The Nobel Price, 2024, 14.10.2024Implausibility of radical life extension in humans in the twenty-first century, Nature Aging, 07.10.2024The relentless push for productivity misconstrues how our brains work, NewScientist, 9.10.2024Artificial intelligence-powered chatbots in search engines: a cross-sectional study on the quality and risks of drug information for patients, BMJ Quality & Safety, 1.10. 2024.Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: Tiktok, Tiktok und Instagram.

Un nuevo estudio publicado en la revista Nature Aging determinó que el ser humano envejece a nivel molecular en dos periodos acelerados, el primero a los 44 años y el segundo a los 60. Conoce las características de este estudio. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Send us a textWhat if you could slow down the impact of aging on your body? Join us on this enlightening episode of Moving Through Midlife as we unpack a groundbreaking study from Nature Aging, revealing how our bodies transform significantly in our mid-40s and early 60s. We'll explore changes in cardiovascular health, metabolism of caffeine and alcohol, immune regulation, carbohydrate metabolism, and kidney function. Learn how these shifts might explain why you can't handle caffeine or alcohol like you used to, and get practical tips on adjusting your lifestyle to better cope with these changes.But that's not all! We'll also discuss the benefits of strength training and how embracing the burn during workouts can lead to substantial growth and transformation. If you're new to weightlifting, we've got advice on finding a trainer and safely increasing your weights. Plus, discover natural ways to boost skin health through supplements and a nutritious diet. Finally, I invite you to join our supportive Facebook community, Moving Through Midlife, where we share experiences and tips for navigating midlife together. Don't forget to leave a review on Apple to help others find our podcast and join this journey towards aging gracefully.Here is the link to the Nature Aging StudyHead to www.movingthroughmidlife.com to join the 12 week coaching program. Support the Show.Head to www.movingthroughmidlife. com to learn moreJoin our Free FB Community:Moving through Midlife (Powered by Form Fit) | Facebookor follow me on IG or Tik Tokcourtney_formfit

Estudo publicado na Nature Aging revela que o envlelhecimento não é progressivo. Acontece de forma abrupta depois dos 40 e aos 60 anos

Feeling like you've aged 10 years in just a few months? New research published in Nature Aging might offer some insight. The study involved 108 volunteers aged between 25 and 75, who provided blood, stool, skin, oral, and nasal samples every few months over a period of up to seven years. Researchers measured levels of 135,000 different molecules, including RNA, proteins, and metabolites, as well as bacteria, fungi, and viruses present on the skin and in the gut. Rather than observing a gradual aging process, the researchers identified two distinct spikes where aging accelerates - one around age 44 and another at age 60. The first spike, at age 44, was linked to changes in molecules associated with cardiovascular disease, as well as a reduced ability to metabolise caffeine, alcohol, and fats. Interestingly, these shifts occurred in both men and women, debunking the notion that they were solely related to perimenopause in women. The second spike, at age 60, was connected to changes in molecules linked to immune function, kidney function, and carbohydrate metabolism. Both age-related spikes also showed significant changes in molecules related to skin and muscle aging. These findings align with the noticeable increase in certain diseases at specific ages, such as cardiovascular disease starting around age 40, and Parkinson's and Alzheimer's diseases becoming more common after age 60. While the study didn't offer strategies to slow down these rapid aging changes, the researchers did suggest that these ages might be key milestones to monitor our health closely. Booking a full medical check-up around these times could be a smart move for preventive care. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Humans have long sought the fountain of youth, and recently scientists have explored the biological basis of aging and potential strategies to reverse the process. Along with groundbreaking discoveries that have enabled extending the lifespan of model organisms, the anti-aging movement has spurred an entire industry focused on stopping the biological clock. In today's episode of Beyond the Abstract, Derek and Dan discuss recent studies about the aging process and debate the promises and pitfalls of this fast-moving field.This episode is sponsored by Proteintech Group, a company that creates reagents for the biomedical sciences so scientists can conduct groundbreaking science. Visit them at www.ptglab.com to find out more.The information presented here is not medical advice. Consult your physician for any questions regarding your personal health.Articles DiscussedAbad et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature, 2013.Ross et al. Depleting myeloid-biased haematopoietic stem cells rejuvenates aged immunity. Nature, 2024.Ocampo et al. In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. Cell, 2016.Wang et al. In vivo partial reprogramming of myofibers promotes muscle regeneration by remodeling the stem cell niche. Nature Communications, 2021.Browder et al. In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. Nature Aging, 2022.Weindruch et al. The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. Journal of Nutrition, 1986.Lu et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature, 2020.Yucel and Gladyshev. The long and winding road of reprogramming-induced rejuvenation. Nature Communications, 2024.Lopez-Otin et al. The Hallmarks of Aging. Cell, 2013.Choudhury et al. Proline restores mitochondrial function and reverses aging hallmarks in senescent cells. Cell Reports, 2024.Zeng et al. Restoration of CPEB4 prevents muscle stem cell senescence during aging. Developmental Cell, 2023.

Une étude toute chaude publiée dans Nature Aging a fait un lien entre un profil alimentaire, certains nutriments en particulier, et un vieillissement plus lent du cerveau. La rencontre Simard-Huot avec Éric Simard, docteur en biologiePour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr

The public discussion in a number of countries around the world expresses worries about what is called an aging society. These countries anticipate a future with fewer younger people who are active members of the economy, and a growing number of older people who need to be supported by the people still in the workforce. It's an inversion of the usual demographic pyramid, with less at the bottom, and more at the top.However, our guest in this episode recommends a different framing of the future – not as an aging society, but as a longevity society, or even an evergreen society. He is Andrew Scott, Professor of Economics at the London Business School. His other roles include being a Research Fellow at the Centre for Economic Policy Research, and a consulting scholar at Stanford University's Center on Longevity.Andrew's latest book is entitled “The Longevity Imperative: Building a Better Society for Healthier, Longer Lives”. Commendations for the book include this from the political economist Daron Acemoglu, “A must-read book with an important message and many lessons”, and this from the historian Niall Ferguson, “Persuasive, uplifting and wise”. Selected follow-ups:Personal website of Andrew ScottAndrew Scott at the London Business SchoolThe book The Longevity Imperative: How to Build a Healthier and More Productive Society to Support Our Longer LivesLongevity, the 56 trillion dollar opportunity, with Andrew Scott - episode 40 in this seriesPopulation Pyramids of the World from 1950 to 2100Thomas Robert Malthus - WikipediaDALYs (Disability-adjusted life years) and QALYs (Quality-adjusted life years) - WikipediaVSL (Value of Statistical Life) - WikipediaThe economic value of targeting aging - paper in Nature Aging, co-authored by Andrew Scott, Martin Ellison, and David SinclairA great-grandfather from Merseyside has become the world's oldest living man - BBC, 5th April 2024Related quotations:Aging is "...revealed and made manifest only by the most unnatural experiment of prolonging an animal's life by sheltering it from the hazards of its ordinary existence" - Peter Medawar, 1951"To die of old age is a death rare, extraordinary, and singular, and, therefore, so much less natural than the others; 'tis the last and extremest sort of dying: and the more remote, the less to be hoped for" - Michel de Montaigne, 1580Music: Spike Protein, by Koi Discovery, available under CC0 1.0 Public Domain DeclarationThe Neil Ashton PodcastThis podcast focuses on explaining the fascinating ways that science and engineering...Listen on: Apple Podcasts Spotify

EPISODE SUMMARY Join scientist and mindset & high-performance coach Claudia Garbutt and accomplished aging researcher José Pedro Castro, PhD, as they discuss aging and health In this episode, we talk about: - What is aging & age-related inflammation - Good inflammation VS bad inflammation - Aging clocks and important biomarkers     Episode NOTES José Pedro Castro completed his PhD in Biomedicine in 2015 by Universidade do Porto Faculdade de Medicina. He then moved to the German Institute of Human Nutrition and joined the Grune Lab (Berlin, Germany) to study how age-related redox and metabolism changes impact the adipose tissue and skeletal muscle.  After completing his aims, he was awarded with the prestigious DFG Max-Kade fellowship and moved to Harvard Medical School (Boston, USA) where he joined the Gladyshev Lab. There, he explored the genetics of aging, age-related diseases and lifespan control from a systems biology perspective.  Recently, and after returning to Portugal, he has joined Logarinho Lab at I3S (Porto, Portugal) after being awarded with the FCT CEEC 5th Edition for Assistant Researcher. Published over 30 articles in peer-reviewed journals such as Cell, Nature Aging or Science Advances. Has received several awards and/or honors, including Early Research Career Award (2010) and Young Investigator Award (2013). He is a reviewer for several scientific journals and a review editor for Redox Biology and Frontiers in Aging. His focus lies on understanding the biology of aging and age-related diseases. Using a combination of experimental and computational approaches he is keen to unravel age-related molecular trajectories leading to chronic diseases.  He is also an assistant professor for Immunology and an invited professor for Biogerontology and Aging and Nutrition. He is involved in several dissemination activities such as the creation of the Portuguese Society for Science and Medicine of Longevity.  On a more personal note, José also dedicates his time to literature by reading as much as he can and writing short fiction stories, but his true desire is to one day write a full novel!   Links: https://www.linkedin.com/in/jos%C3%A9-pedro-castro-phd-92528620   ------------ Click this link to listen on your favorite podcast player and if you enjoy the show, please leave a rating & review: https://linktr.ee/wiredforsuccess   Help me keep this show running and awesome: Hit subscribe and join the tribe! THANK YOU for your support! 

Today we're diving into some groundbreaking research that could potentially change the game when it comes to aging. Our spotlight is on a recent study published in Nature Aging by Cold Spring Harbor Laboratory, and it's all about using a "living" drug called chimeric antigen receptor(CAR) T Cells to tackle those pesky senescent cells. But before we get into the nitty-gritty, let's break it down for you in simple terms. Imagine your body as a city and senescent cells are like those old, rundown buildings that just refuse to budge. They don't function properly, and worse, they release signals that can negatively affect the surrounding healthy cells. These cells are dysfunctional and shoot out signals that wreak havoc on their healthy neighbors. Now, the researchers at CSHL is proposing a superhero-like solution: CAR T Cells.

Mit dem richtigen Lebensstil lässt sich die Chance auf ein langes und gesundes Leben, auch Longevity genannt, erhöhen. Wie wir achtsam mit unserer Gesundheit umgehen.**********Quellen aus der Folge:Waziry, R., Ryan, C. P., Corcoran, D. L., Huffman, K. M., Kobor, M. S., Kothari, M., ... & Belsky, D. W. (2023). Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nature Aging, 3(3), 248-257. Jacobs, T. L., Epel, E. S., Lin, J., Blackburn, E. H., Wolkowitz, O. M., Bridwell, D. A., ... & Saron, C. D. (2011). Intensive meditation training, immune cell telomerase activity, and psychological mediators. Psychoneuroendocrinology, 36(5), 664-681. **********Dianes und Main Huongs Empfehlungen:Michalsen, A. (2019). Mit Ernährung heilen: Besser essen–einfach fasten–länger leben. Neuestes Wissen aus Forschung und Praxis. Suhrkamp Verlag.Esch, Tobias, “Wofür stehen sie morgens auf?”, Gäfe und Unzer, 2023 **********Mehr zum Thema bei Deutschlandfunk Nova:Persönlichkeitsmuster: Achtsam introvertiert seinAchtsam hören: Wie Musik uns im Alltag hilftEnde: Achtsam Abschied nehmen**********Den Artikel zum Stück findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: Tiktok und Instagram.**********Ihr habt Anregungen, Ideen, Themenwünsche? Dann schreibt uns gern unter achtsam@deutschlandfunknova.de

Um estudo desenvolvido por pesquisadores da Universidade Federal do Rio Grande do Sul (UFRGS) revelou que pessoas portadoras do gene apolipoproteína E possuem de 3 a 15 vezes mais risco de desenvolverem Alzheimer. O artigo, publicado recentemente na revista especializada Nature Aging, apontou que este gene está presente em 26% da população mundial e é capaz de gerar um acúmulo maior de proteína no cérebro, o que resulta na morte de neurônios, e consequentemente, a atrofia cerebral. Em entrevista à CBN Vitória, o pesquisador do estudo, doutorando em bioquímica e aluno de medicina da Universidade Federal do Rio Grande do Sul (UFRGS), João Pedro Ferrari Souza, explica como esse gene influencia no aumento dos riscos do Alzheimer, e fala sobre os próximos passos da pesquisa na busca por soluções de tratamento. Ouça a conversa completa!

Die Themen in den Wissensnachrichten: +++ "Salz-Lakritz" als sechster Grundgeschmack? +++ Spermidin könnte Fruchtbarkeit von Frauen verbessern +++ Gesellschaften träumen unterschiedlich +++**********Weiterführende Quellen zu dieser Folge:The proton channel OTOP1 is a sensor for the taste of ammonium chloride, Nature Communications, 5.10.2023Polyamine metabolite spermidine rejuvenates oocyte quality by enhancing mitophagy during female reproductive aging, Nature Aging, 16.10.2023Evidence for an emotional adaptive function of dreams: a cross-cultural study, Scientific Reports, 2.10.2023Facing Scrutiny, a Museum That Holds 12,000 Human Remains Changes Course, New York Times, 15.10.2023Large sensory volumes enable Southern elephant seals to exploit sparse deep-sea prey, PNAS, 16.10.2023Energieeinsparung in Bäckereien mittels einer neuartigen textilen Backunterlage, Fraunhofer-Zentrum für Hochtemperatur-Leichtbau HTL, 16.10.2023**********Ihr könnt uns auch auf diesen Kanälen folgen: Tiktok und Instagram.

Puntata 477 con Andrea e Marco in condizione di conduzione e Valeria in esterna. In apertura parliamo della stupidità dei fisici che quando vanno alle conferenze non vedono nulla dei luoghi ove si tengono gli incontri, poi di gigantesco ammasso di galassie su una struttura sferica, chiamato Ho'oleilana.Valeria intervista Nicola Vannini che dirige il laboratorio di immunosenescence and stem cell metabolism al Ludwig Cancer Institute dell'Università di Losanna. Nicola ci racconta del recente studio pubblicato su Nature Aging in cui hanno identificato una molecola capace di aumentare il riciclo dei mitocondri e quindi ringiovanire le cellule staminali ematopoietiche.Dopo la barza Andrea parla di un esperimento che cerca di determinare l'elusivisssimerrima massa del neutrino dal decadimento del trizio. Inoltre ricordiamo che il 7 ottobre ci sarà un incontro all'acquario di Genova e pizza a seguire con chi ci vuole non troppo male.

Implications for the Future- In essence, this groundbreaking research indicates that by encouraging the recycling of mitochondria using Urolithin A, it is possible to reverse the aging process within the hematopoietic and immune systems. These findings hold immense promise for the development of interventions targeted at addressing age-related health conditions in older individuals and pave the way for envisioning clinical trials. #urolithinA #ellagic #ellagitannins Girotra, M., Chiang, Y., Charmoy, M., Ginefra, P., Hope, H. C., Bataclan, C., Yu, Y., Schyrr, F., Franco, F., Geiger, H., Cherix, S., Ho, P., Naveiras, O., Auwerx, J., Held, W., & Vannini, N. (2023). Induction of mitochondrial recycling reverts age-associated decline of the hematopoietic and immune systems. Nature Aging, 1-10. https://doi.org/10.1038/s43587-023-00473-3 An, L., Lu, Q., Wang, K., & Wang, Y. (2023). Urolithins: A Prospective Alternative against Brain Aging. Nutrients, 15(18), 3884. https://doi.org/10.3390/nu15183884 --- Support this podcast: https://podcasters.spotify.com/pod/show/ralph-turchiano/support

A Redmi Note 13 Pro+ hamarosan érkezik Dimensity 7200-Ultra chipsettel és 200 MP-os kamerával Android Portál     2023-09-11 08:38:27     Mobiltech Telefon Samsung Xiaomi A Xiaomi hamarosan bemutatja a Redmi Note 13 Pro+-t, és most megismerhetjük néhány kulcsfontosságú adatát. Az új telefonban a Dimensity 7200-Ultra – a Mediatek 4 nm-es platformjának felturbózott változata – fut majd. Emellett egy 200 MP-es kamerával is rendelkezik majd, Samsung ISOCELL érzékelővel, amely továbbfejlesztett feldolgozással érkezik a k Az IBM-nél is kiadták az ukázt: vissza az irodába! Bitport     2023-09-11 11:03:02     Infotech USA IBM Az amerikai óriás szoftveres részlegénél dolgozóknak minimum heti háromszor meg kell jelleni a munkahelyén, hogy "tartalmas időt" tölthessenek a menedzserekkel. Nagy durranásra készül a Huawei mmonline.hu     2023-09-11 06:36:42     Mobiltech Spanyolország Barcelona Huawei Okosóra Szeptember 14-én új viselhető okoseszközöket mutat be a Huawei Barcelonában. A gyártó új, „Fashion Forward” koncepciója és az arra épülő eseménye a technológia és a stílus összekapcsolására összpontosít, és a következő negyedévben olyan új okosóra-termékekkel jelentkezik, amelyek innovatív funkcióikkal forradalmasíthatják a piacot. Új viselhető oko Sikerült előállítani megtermékenyített petesejt nélkül egy embriót Player     2023-09-11 10:30:13     Infotech Izrael Embrió Izraeli tudósok megtermékenyített petesejt nélkül, szintetikus embriómodellt állítottak elő. Egy komplett házat mutatott be az LG Európa legnagyobb technológiai kiállításán Rakéta     2023-09-11 06:09:05     Infotech Energia Kiállítás A Smart Cottage névre keresztelt "okoskunyhóban" szinte minden négyzetméterre jut egy intelligens berendezési tárgy, a ház energiaellátási rendszere pedig akár azt is lehetővé teszi, hogy egyáltalán ne kelljen a hálózatról vennünk az áramot. Oltásellenes influenszerrel szemben nyert pert a YouTube PCWorld     2023-09-11 11:21:01     Infotech Bíróság Védőoltás YouTube Influencer A bíróság nem osztotta a véleményt, hogy a platform jogtalanul törölte a félrevezető tartalmakat. Döntetlen a mesterséges intelligenciák csatájában IT Business     2023-09-11 11:57:02     Mobiltech Anglia Mesterséges intelligencia Vajon Raffaello, az itáliai reneszánsz egyik zseniális mesterének ecsetét dicséri a "de Brécy Tondo" néven ismert festmény? A kérdés eldöntésére mesterséges intelligenciával támogatott tanulmányokat rendeltek – a két MI pedig pontosan ellentétes végeredményre jutott. A Madonnát és a kisgyermek Jézust ábrázoló festmény az angliai Bradfordban lévő Ca Török kiberbűnözők összefogtak a nemrégiben az országba érkezett orosz hackerekkel 444.hu     2023-09-11 13:06:58     Infotech Hacker Kibertámadás Az oroszok kifinomult kódokat tanítanak a törököknek, míg ők a nyugat-európai kapcsolataikat kihasználva jobb árakat tudtak elérni a hatékonyan szervezett adathalmazokért. Egy év késéssel átadták az NMHH új, 18 milliárdból készült komplexumát Media1     2023-09-11 12:28:38     Mobiltech Tavasz NMHH Médiatanács Csütörtökön átadták az Nemzeti Média- és Hírközlési Hatóság (NMHH) új, többfunkciós műszaki épületét, amelynek tervezése már 2016-ban megkezdődött, és eredetileg 2022 tavaszára akartak vele elkészülni. Az épületegyüttesben mérőlabor és a hozzá tartozó mérőkamrák, szerverközpont, konferenciaterem, mélygarázs, tárgyalók és irodák is helyet kaptak. A Emberi vesét növesztettek sertésekben 24.hu     2023-09-11 15:10:03     Tudomány Embrió A kutatók öt embriót elemeztek, és kiderült, hogy a fejlődési szakaszukhoz képest funkcionális, egészséges vesékkel rendelkeznek.  Ez lenne az örök élet széruma? Nyíregyháza     2023-09-11 10:51:27     Belföld Mesterséges intelligencia A fiatal vér megfiatalította az öreg egereket és növelte az élettartamukat: a HUN-REN SZTAKI mesterséges intelligencia kutatója is részt vett a Nature Aging folyóiratban megjelent tanulmányban. Finn börtönökből tanítják a mesterséges intelligenciát PhoneBazis     2023-09-11 15:09:08     Mobiltech Börtön Mesterséges intelligencia Finnország Startup A finn Metroc startup, amely építési projektek keresőmotorára specializálódott, börtönbüntetésüket töltő elítélteket használ fel, hogy azok segítsenek kiképezni AI rendszereiket. Ebben a cikkben felfedezzük, hogyan működik ez az ötlet és milyen következményei vannak. “Marmalade”, hat évet kapott a Hämeenlinna börtönben, ami Finnország egyik legbizt Higiénikus Kuka robotok hódítják meg az élelmiszeripart Gyártástrend     2023-09-11 09:51:06     Cégvilág Élelmiszer Robot A szigorú követelmények miatt az élelmiszeriparban egyre inkább előtérbe kerül a robottechnológia alkalmazása a hatékonyság és a higiénia növelése érdekében. A Kuka széles portfóliója ezen a területen az egész világon egyedülálló, mivel a Kuka Ho (higiénikus olaj) robotjait úgy tervezték megfeleljenek a legmagasabb higiéniai előírásoknak és megoldá

A Redmi Note 13 Pro+ hamarosan érkezik Dimensity 7200-Ultra chipsettel és 200 MP-os kamerával Android Portál     2023-09-11 08:38:27     Mobiltech Telefon Samsung Xiaomi A Xiaomi hamarosan bemutatja a Redmi Note 13 Pro+-t, és most megismerhetjük néhány kulcsfontosságú adatát. Az új telefonban a Dimensity 7200-Ultra – a Mediatek 4 nm-es platformjának felturbózott változata – fut majd. Emellett egy 200 MP-es kamerával is rendelkezik majd, Samsung ISOCELL érzékelővel, amely továbbfejlesztett feldolgozással érkezik a k Az IBM-nél is kiadták az ukázt: vissza az irodába! Bitport     2023-09-11 11:03:02     Infotech USA IBM Az amerikai óriás szoftveres részlegénél dolgozóknak minimum heti háromszor meg kell jelleni a munkahelyén, hogy "tartalmas időt" tölthessenek a menedzserekkel. Nagy durranásra készül a Huawei mmonline.hu     2023-09-11 06:36:42     Mobiltech Spanyolország Barcelona Huawei Okosóra Szeptember 14-én új viselhető okoseszközöket mutat be a Huawei Barcelonában. A gyártó új, „Fashion Forward” koncepciója és az arra épülő eseménye a technológia és a stílus összekapcsolására összpontosít, és a következő negyedévben olyan új okosóra-termékekkel jelentkezik, amelyek innovatív funkcióikkal forradalmasíthatják a piacot. Új viselhető oko Sikerült előállítani megtermékenyített petesejt nélkül egy embriót Player     2023-09-11 10:30:13     Infotech Izrael Embrió Izraeli tudósok megtermékenyített petesejt nélkül, szintetikus embriómodellt állítottak elő. Egy komplett házat mutatott be az LG Európa legnagyobb technológiai kiállításán Rakéta     2023-09-11 06:09:05     Infotech Energia Kiállítás A Smart Cottage névre keresztelt "okoskunyhóban" szinte minden négyzetméterre jut egy intelligens berendezési tárgy, a ház energiaellátási rendszere pedig akár azt is lehetővé teszi, hogy egyáltalán ne kelljen a hálózatról vennünk az áramot. Oltásellenes influenszerrel szemben nyert pert a YouTube PCWorld     2023-09-11 11:21:01     Infotech Bíróság Védőoltás YouTube Influencer A bíróság nem osztotta a véleményt, hogy a platform jogtalanul törölte a félrevezető tartalmakat. Döntetlen a mesterséges intelligenciák csatájában IT Business     2023-09-11 11:57:02     Mobiltech Anglia Mesterséges intelligencia Vajon Raffaello, az itáliai reneszánsz egyik zseniális mesterének ecsetét dicséri a "de Brécy Tondo" néven ismert festmény? A kérdés eldöntésére mesterséges intelligenciával támogatott tanulmányokat rendeltek – a két MI pedig pontosan ellentétes végeredményre jutott. A Madonnát és a kisgyermek Jézust ábrázoló festmény az angliai Bradfordban lévő Ca Török kiberbűnözők összefogtak a nemrégiben az országba érkezett orosz hackerekkel 444.hu     2023-09-11 13:06:58     Infotech Hacker Kibertámadás Az oroszok kifinomult kódokat tanítanak a törököknek, míg ők a nyugat-európai kapcsolataikat kihasználva jobb árakat tudtak elérni a hatékonyan szervezett adathalmazokért. Egy év késéssel átadták az NMHH új, 18 milliárdból készült komplexumát Media1     2023-09-11 12:28:38     Mobiltech Tavasz NMHH Médiatanács Csütörtökön átadták az Nemzeti Média- és Hírközlési Hatóság (NMHH) új, többfunkciós műszaki épületét, amelynek tervezése már 2016-ban megkezdődött, és eredetileg 2022 tavaszára akartak vele elkészülni. Az épületegyüttesben mérőlabor és a hozzá tartozó mérőkamrák, szerverközpont, konferenciaterem, mélygarázs, tárgyalók és irodák is helyet kaptak. A Emberi vesét növesztettek sertésekben 24.hu     2023-09-11 15:10:03     Tudomány Embrió A kutatók öt embriót elemeztek, és kiderült, hogy a fejlődési szakaszukhoz képest funkcionális, egészséges vesékkel rendelkeznek.  Ez lenne az örök élet széruma? Nyíregyháza     2023-09-11 10:51:27     Belföld Mesterséges intelligencia A fiatal vér megfiatalította az öreg egereket és növelte az élettartamukat: a HUN-REN SZTAKI mesterséges intelligencia kutatója is részt vett a Nature Aging folyóiratban megjelent tanulmányban. Finn börtönökből tanítják a mesterséges intelligenciát PhoneBazis     2023-09-11 15:09:08     Mobiltech Börtön Mesterséges intelligencia Finnország Startup A finn Metroc startup, amely építési projektek keresőmotorára specializálódott, börtönbüntetésüket töltő elítélteket használ fel, hogy azok segítsenek kiképezni AI rendszereiket. Ebben a cikkben felfedezzük, hogyan működik ez az ötlet és milyen következményei vannak. “Marmalade”, hat évet kapott a Hämeenlinna börtönben, ami Finnország egyik legbizt Higiénikus Kuka robotok hódítják meg az élelmiszeripart Gyártástrend     2023-09-11 09:51:06     Cégvilág Élelmiszer Robot A szigorú követelmények miatt az élelmiszeriparban egyre inkább előtérbe kerül a robottechnológia alkalmazása a hatékonyság és a higiénia növelése érdekében. A Kuka széles portfóliója ezen a területen az egész világon egyedülálló, mivel a Kuka Ho (higiénikus olaj) robotjait úgy tervezték megfeleljenek a legmagasabb higiéniai előírásoknak és megoldá

Dr. Carolina Reis Oliveira and Dr. Alessandra Zonari are the co-founders of OneSkin, a company developing science-backed skincare products to reverse skin aging at the cellular level. In this episode, Carolina and Alessandra tell host Dr. Chris Patil how OneSkin is leveraging recent advances in longevity science to create novel peptides that target senescent cells and inflammation in aged skin. Their lead ingredient, OS-1, is a peptide capable of reducing biological age and senescence burden in human skin models.They explain their rigorous discovery process, including screening peptide libraries in cellular models of skin aging, which were described in a recent paper in Nature Aging. Next, they share how they translated this scientific research into an effective, consumer-friendly skincare product line and brand. Listeners will gain insights into OneSkin's unique approach bridging cosmetics and cutting-edge geroscience.Key topics:Why skin health and appearance are important markers of overall agingThe cellular and molecular changes underlying skin agingHow most skincare products focus on temporary effects vs. targeting root causesScreening peptide libraries in cellular models to discover senolytic/senomorphic candidatesDiscovery and testing of lead peptide OS-1 in 3D skin models and human trialsValidating safety and efficacy to meet cosmetics regulatory requirementsLaunching a science-backed skincare brand and resonating with educated consumersOngoing R&D to expand into new anti-aging applications and delivery methodsQuotes:Quotes have been lightly edited for clarity."Obviously, we look at our skin from the lens of aesthetics or of beauty. But our skin is our largest organ, and its main function is to protect our whole body against pathogens and different types of environmental stressors. As the skin ages and deteriorates, the function also gets compromised."“That's one of the things that we're interested in and exploring at OneSkin: not only how to improve your appearance, but also how to improve your skin function so it can aid in your overall health.”"We realized none of the products out there were developed with the rationale of targeting aging itself.""When we treat dermal fibroblasts with this peptide, we could decrease the amount of senescent cells by 40–50%.""More and more, the population is getting educated. They don't want just marketing claims, they want to understand and trust brands that can really bring proof.""People are more open to say, okay, if I need to put something on my skin, I should use a company that's actually doing real science.""Our primary goal is to continue to be the most innovative company when it comes to skin aging, and to continue to be at the forefront of aging research applied to skin."Links: Email questions, comments, and feedback to podcast@bioagelabs.comTranslating Aging on Twitter: @bioagepodcastBioAge Labs Website bioagelabs.comBioAge Labs Twitter @bioagelabsBioAge Labs LinkedInOneSkin company page

Dr. Felix Wong is a co-founder of Integrated Biosciences, an early-stage biotech company developing next-generation therapeutics for cellular rejuvenation. He is also a postdoc at MIT and the Broad Institute and was a lead author on a recent Nature Aging paper describing the use of graph neural networks to discover new senolytic compounds.In this episode, Felix and host Chris Patil have an in-depth discussion about using machine learning to accelerate drug discovery, specifically to target cellular senescence. They explore how graph neural networks were trained on screening data to evaluate large chemical spaces and identify new senolytic molecules with medicinal properties superior to those of previously known compounds.Key topics:What cellular senescence is and why selectively eliminating senescent cells may have therapeutic benefits for aging and age-related diseasesLimitations of traditional high-throughput screening approaches and the vastness of chemical spaceHow graph neural networks work and how Felix's team trained them on senolytic screening dataApplying the models to search much larger chemical libraries and identify promising new senolytic scaffoldsExperimental validation and characterization of hits from the AI screeningThe potential to use this machine learning approach more broadly for phenotypic drug discoveryFelix's new company Integrated Biosciences and their mission to control cellular stress responses using synthetic biology and AIQuotes:Quotes have been lightly edited for clarity."We found that machine learning models might allow us to more productively search chemical space and increase our working hit rates.""What was fascinating to us about senescence cells is that, unlike other pathologies or diseases, these cells are not really characterized by a single target.""The quality of any machine learning model is limited by the quality of the training data. And that in turn is limited by how good your screens are, and how good your understanding of the biology is."“That's really what machine learning is doing, trying to think about things in a very high dimensional manner. And then trying to build models that help to separate what is positive and what is negative.”“So what ideally we would want is for any model to be able to generalize, to be able to predict chemical scaffolds that the model has not previously seen, and positively identify those scaffolds as new senolytics.”"Ideally, we would like to treat aging and age-related diseases, just like how antibiotics treat bacterial infections."“At Integrated, we're trying to kind of look at these stress responses holistically. We think that senescence is only a piece of the bigger puzzle.”Links: Email questions, comments, and feedback to podcast@bioagelabs.comTranslating Aging on Twitter: @bioagepodcastBioAge Labs Website bioagelabs.comBioAge Labs Twitter @bioagelabsBioAge Labs LinkedInIntegrated Biosciences

Eating fewer calories appears to slow the pace of aging and increase longevity in healthy adults, according to a study published in the journal Nature Aging. The study, which was funded by the National Institute on Aging, part of the National Institutes of Health, is the first-ever randomized controlled trial that looked at the long-term impact of calorie restriction. It adds to an already large body of evidence that a calorie-restricted diet can provide substantial health benefits, including delayed aging, said the study's senior author, Dan Belsky, who is assistant professor of epidemiology at Columbia University's Mailman School of Public Health in New York City. Wellness Expert, Speaker & Author Dr. Mary Warren joins JT to discuss this new study.

Last Thursday, scientists at Columbia University published a new study finding that cutting down on calories could lead to longer lives. In the phase 2 trial, 220 healthy people without obesity dropped their calories significantly, and a test of their biological age showed that their rate of aging slowed by 2 to 3 percent in over a couple of years. Small though that may seem, it amounts to a decline of about 10 percent in the risk of death as people get older, according to the researchers' estimate. That's basically the same as quitting smoking.Previous research has shown that restricting calories results in longer lives for mice, worms and flies. This research is unique because it applies those findings to people. It was published in Nature Aging.But what did the researchers actually show? Does the new paper point to anything people should be doing to have longer, healthier lives? Spoiler alert: Maybe, but first, you'd want to consult a medical expert about it. I had the chance to chat with someone with inside knowledge of the research -- Dr. Evan Hadley, director of the National Institute of Aging's Division of Geriatrics and Clinical Gerontology, which funded the study. Dr. Hadley describes how the research participants went about reducing their calories, as well as the risks and benefits involved. He also explains the "aging clocks" used to measure the benefits.Leaps.org is a not-for-profit initiative that publishes award-winning journalism, popularizes scientific progress on social media, and hosts events about bioethics and the future of humanity. Visit the platform at www.leaps.org. Podcast host Matt Fuchs is editor-in-chief of Leaps.org.

Please join author Subodh Verma and Guest Editor Christopher Granger as they discuss the article "Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-host. I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr. Peder Myhre: And I'm Dr. Peder Myhre, social media editor and doctor at Akershus University Hospital at University of Oslo in Norway. Dr. Carolyn Lam: Peder, I am so excited to be discussing this issue. So many great articles and a feature discussion coming up on the SGLT2 inhibitor, empagliflozin. And do you think it's got effects on left ventricular remodeling in people without diabetes? Very interesting question. Dr. Peder Myhre: That is so interesting, Carolyn. I can't wait to hear this discussion. Dr. Carolyn Lam: Yep, I agree, but we got to wait till we discuss the other papers in today's issue. I want to go first. So we know that non-vitamin K oral anticoagulants, or NOACs, they've become the standard therapy for preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation. But, what is the effectiveness and safety of NOACs in patients on dialysis? That is hemodialysis. The AXADIA-AFNET 8 study sought to test the hypothesis that apixaban would be non-inferior to vitamin K antagonists in these very patients undergoing hemodialysis. Dr. Peder Myhre: Oh wow. This is really a gap of knowledge that we've been waiting to hear more about. NOACs in patients with hemodialysis. Tell us about this trial, Carolyn. Dr. Carolyn Lam: Sure. So this is from corresponding author, Dr. Reinecke, and colleagues, from University of Munster in Germany. And it's an investigator initiated prospective randomized open-blinded outcome assessment of 97 patients with atrial fibrillation on chronic hemodialysis randomized to either apixaban 2.5 mg BID, or a vitamin K antagonist, aiming for an INR between 2 and 3. Over a median follow-up time of 429 days for apixaban, and 506 days for the vitamin K antagonist, the composite primary safety outcome of first, major bleeding, clinically relevant, non-major bleeding, or all cause death, occurred in 46% of patients on apixaban, and 51% of patients on the vitamin K antagonist. That would be a hazard ratio of 0.91, with a p for non-inferiority being 0.157. How about the primary efficacy outcome? While this was a composite of ischemic stroke, all cause death, myocardial infarction, or deep vein thrombosis, and/or pulmonary embolism, and that occurred in 21% of patients on apixaban and 31% of patients on the vitamin K antagonists. Again, no difference when there was testing. So, in summary, Peder, there were no differences in the safety or efficacy observed between apixaban and vitamin K antagonists in patients with atrial fibrillation on chronic hemodialysis. Of note, however, even receiving oral anticoagulations, these patients remain at very high risk of cardiovascular events. So these data really support the consideration of apixaban for prevention of cardiovascular complications in patients with atrial fibrillation on chronic hemodialysis, but larger studies are definitely needed. Dr. Peder Myhre: Oh wow, Carolyn, that is so clinically relevant. And the next paper is also a clinically relevant paper. And it comes to us from the SPRINT authors. And to remind you, the SPRINT study was a study of intensive systolic blood pressure lowering compared to standard blood pressure lowering. And the results demonstrated that there was a robust reduction in both heart failure endpoints and all cause mortality. And in this sub-study that comes to us from corresponding author Jarett Berry from University of Texas Tyler School of Medicine, these authors look at the mechanisms through which intensive blood pressure lowering reduces the risk of these endpoints. And given the important role of cardiac injury and neurohormonal activation in the pathways leading from hypertension to heart failure, and strong association that has been observed between hypertension and levels of cardiac troponin and NT-proBNP, the authors hypothesized that intensive systolic blood pressure lowering would decrease levels of high sensitivity cardiac troponin T and NT-proBNP. Dr. Carolyn Lam: Cool. That's interesting. So how did they do this, and what did they find? Dr. Peder Myhre: So, as expected, Carolyn, the authors found that increases in troponin and NT-proBNP from baseline to 1 year were associated with a higher risk of heart failure and death. And there were really no significant interaction by treatment assignment. But let's look at the changes in troponin. And these results showed that randomization to intensive blood pressure lowering versus standard blood pressure lowering resulted in a significant 3% increase in cardiac troponin T level over 1 year follow up, and a higher proportion of participants with more than 50% increase, and that's with an odds ratio of 1.47. And Carolyn, in contrast, NT-proBNP decreased by 10% in intensive blood pressure arm. And these patients had substantially lower probability of increasing more than 50% in NT-proBNP, with an odds ratio of 0.57 compared to the standard arm. And now, to the most interesting part of this analysis, Carolyn, the association of randomized treatment assignment on changes in troponin was completely attenuated after accounting for changes in eGFR during the follow up, whereas the association of treatment with NT-proBNP changes were completely attenuated after adjusting for changes in systolic blood pressure. So Carolyn, the authors highlight in their discussion the importance of non-cardiac factors influencing variation in cardiac biomarkers, and raise questions about the potential role of cardiac troponin T as a surrogate marker for heart failure or death in blood pressure lowering studies. Dr. Carolyn Lam: Wow, very interesting. Thanks, Peder. Can I tell you now about a preclinical study? Very interesting, because it shows that cardiac inflammation and hypertrophy are regulated by a heart-brain interaction. Dr. Peder Myhre: Wow, Carolyn, a heart-brain interaction. I'm excited to hear more about this. Please explain. Dr. Carolyn Lam: I'd love to, but first some background. Interleukin-1 beta, now that is a pro-inflammatory cytokine that causes cardiac hypertrophy and heart failure. I need to familiarize you with this, the nucleotide-binding domain leucine-rich containing family, pyrin domain-containing-3, NLRP3 for short, which is an inflammasome, which is a cytosolic multiprotein complex that mediates active interleukin-1 beta production. Okay? So you know these terms, and now I want to tell you about the study. This is an elegant series of experiments performed by co-corresponding authors, Dr. Higashikuni, from University of Tokyo, and Dr. Sata, from Tokushima University Graduate School of Medicine, and their colleagues. They first showed that genetic disruption of the NLRP3 inflammasome resulted in significant loss of interleukin-1 beta production, cardiac hypertrophy, and contractile function during pressure overload. Next, a bone marrow transplantation experiment revealed an essential role of NLRP3 inflammasome in cardiac non-immune cells in myocardial interleukin-1 beta production and the cardiac phenotype. It was extracellular ATP released from sympathetic nerve terminals that induced the hypertrophic changes of cardiac cells in an NLRP3 and interleukin-1 beta dependent manner in vitro. And finally, depletion of ATP release from sympathetic efferent nerves, or ablation of cardiac afferent nerves, or a lipophilic beta-blocker, all reduced cardiac extracellular ATP, and inhibited the NLRP3 inflammasome activation, the interleukin-1 beta production, and the adaptive cardiac hypertrophy during pressure overload. So all of this suggests that controlling the neuronal brain signals might have therapeutic potential for the treatment of hypertensive heart disease. Neat, huh? Dr. Peder Myhre: Oh, that is so interesting. The heart and brain interaction. And, Carolyn, we're going to stay in the field of preclinical science. And now we're going to talk about another field that is really interesting, and that is regeneration of cardiomyocytes. Because, Carolyn, developmental cardiac tissue holds remarkable capacity to regenerate after injury, and consists of regenerative mononuclear and deployed cardiomyocytes. Whether reprogramming metabolism promotes persistence of these regenerative mononuclear and deployed cardiomyocytes that enhance cardiac function in repair after injury is unknown. Therefore, these researcher, led by corresponding author, Mohsin Khan, from Temple University School of Medicine, investigated whether the RNA binding protein, LIN28a, which is a master regulator of cellular metabolism, plays a role in cardiac repair following injury. Dr. Carolyn Lam: Wow. That is always, always interesting, regeneration and repair following injury. So what did the authors find? Dr. Peder Myhre: Well, Carolyn, through a number of elegant experiments, the authors made the following key findings. For the first time, they documented a role for RNA binding protein LIN28A in regulating cardiomyocyte turnover in the postnatal and adult heart. And LIN28a overexpression promotes cardiomyocyte cell cycle activity during postnatal development and extends cardiac regenerative ability of the mammalian heart to postnatal day 7. And in the adult heart, the authors could demonstrate that LIN28a drives new myocyte formation, augmenting cardiac structure and function after myocardial injury. And Carolyn, I'm sure you're going to ask the clinical implications of this study. Dr. Carolyn Lam: Indeed. Dr. Peder Myhre: And that is that these results may suggest a novel translational role for LIN28a based strategy to replenish cardiomyocytes in the adult heart after injury. Dr. Carolyn Lam: Very nice, Peder. Thank you. Also in the issue is a Research Letter by Dr. Bick on interleukin-6 receptor polymorphism attenuates clonal hematopoiesis mediated coronary artery disease risk among many individuals in the UK Biobank. There's also Cardiology News by Tracy Hampton, where she highlights few really interesting things, like aging cardiomyocytes accumulate new genetic mutations that was published in Nature Aging, cytokines promote tissue repair after a heart attack in mice, and that was published in Science, and scientists identifying molecular alterations in a failing heart at a single cell resolution, which was published in Nature. Dr. Peder Myhre: And there are a couple of other papers also in this issue, Carolyn. And there's first, an exchange of letters by Drs. Halushka, Lu, and Mayr, regarding the article "Circulating MicroRNA-122-5p is Associated with a Lack of Improvement in Left Ventricular Function after TAVR and Regulates Viability of Cardiomyocytes Through Extracellular Vesicles." And finally, we have an "On My Mind" piece by doctors Monda and Limongelli entitled "An Integrated Sudden Cardiac Risk Prediction Model for Patients with Hypertrophic Cardiomyopathy." Dr. Carolyn Lam: Oh, nice. Nice full issue. Thank you, Peder. Let's go to our feature discussion now. Shall we? Dr. Peder Myhre: Let's go. Dr. Greg Hundley: Welcome listeners to this feature discussion on January 24th. And we have with us Dr. Subodh Verma, from St. Michael's University in Toronto, Canada. And a guest editor, Dr. Christopher Granger, from Duke University in Durham, North Carolina. Welcome gentlemen. Well, Subodh, we will start with you. Can you describe for us some of the background information that went into the preparation of your study, and what was the hypothesis that you wanted to address? Dr. Subodh Verma: First, my great pleasure to be here, and thank you very much for the opportunity to discuss this paper with your viewers. As you know, SGLT2 inhibitors have been truly transformative therapies. From a heart failure perspective, we know that they prevent incident heart failure in people with diabetes who have vascular disease or risk factors. They also have been shown to treat prevalent heart failure in people with heart failure and either a reduced, mildly reduced, or preserved ejection fraction independent of glycemic status. And really, these have been the basis of very strong recommendations to use these agents in the prevention of heart failure in people with diabetes, and also in the treatment of prevalent heart failure in people with and without diabetes. Now, the fact that these drugs have such broad effects in people with heart failure has led to a theory that maybe these drugs could be introduced earlier on in the natural history of heart failure in people who neither have diabetes nor have significant heart failure, the so-called sort of stage A or stage B patient. But there really have been no clinical trials evaluating this question. There've been a lot of translational randomized trials that have provided some mechanistic insights about LV remodeling in people with diabetes or in people with prevalent heart failure. And we hypothesized that maybe the first step to evaluate whether SGLT2 inhibitors may have favorable effects on cardiac remodeling in people without diabetes or without heart failure would be to conduct a randomized double-blind control trial looking at indices of left ventricular remodeling in a population that I've just described. Dr. Greg Hundley: Very nice, Subodh. So you've started us into your study design. Maybe describe that a little more fully, and then who was included in your study population? Dr. Subodh Verma: So EMPA-HEART 2 CardioLink was a multi-center double-blind placebo control randomized trial in which we studied the effects of empagliflozin, an SGLT2 inhibitor, at a dose of 10 mg per day versus placebo in people who did not have type 2 diabetes or significant heart failure. We included people who were adults between the age of 40 and 80 who met 1 of 2 entry criteria. Either they had to have one major criteria, which was an increase in left ventricular mass index by specific echo criteria or MRI criteria, or they could have increased LVH as identified by ECG or by intraventricular septal or posterior wall thickness. They could also get in if they had resistant hypertension, hypertension despite being on 3 antihypertensive agents, or the second strata was entry through 2 minor criteria, which included a history of myocardial infarction, a GFR between 30 or 60, or evidence of overweight or obesity. Dr. Greg Hundley: And how many subjects did you randomize? Dr. Subodh Verma: So we randomized, of the 318 that we screened, 169 were randomized to receive empagliflozin 10 mg or a placebo. Patients had a baseline cardiac MRI done, and then the exposure was 6 months. They had a follow-up MRI at the end of 6 months. And the primary outcome measure was a 6-month change in left ventricular mass index from baseline to 6 months between the two groups. Dr. Greg Hundley: Very nice. And so , Subodh, can you describe for us now, what did you find? What were your study results? Dr. Subodh Verma: So, first and foremost, what we found in terms of baseline characteristics was that we enrolled a population of people with a mean age of around 60 with a BMI of around 30 kg/m2, predominantly men, about 80% or so were men. These were patients who did not have significant heart failure. The NT-proBNP at baseline was around 50 pg/mL. The eGFR was around 80 mL/minute, and the vast majority of these patients actually had a history of hypertension. Of course, none of them had diabetes by definition. The hemoglobin A1C was around 5.8%. Now what we found was, despite the fact that we went after patients who we thought would be enriched for a baseline increase in LV mass indices, the baseline LV mass index was mildly elevated, was around 63 g/m2. And over the course of 6 months, we did not find any significant difference in terms of LV mass regression between the placebo and empagliflozin groups. In fact, the adjusted treatment effect was minus 0.30 g/m2, which was not statistically significant. No other differences were found in terms of other indices of a remodeling, including left ventricular and diastolic or end systolic volume indices or in terms of left ventricular ejection fraction. There was a 2% increase in ejection fraction, and the p-value for that was 0.07, but really was not statistically significant. Dr. Greg Hundley: And very nice. And realizing that women may have smaller LV masses, any stratified analysis that evaluated effects on men versus women? And then what about, perhaps in the higher quartile versus lower quartile, of age? Dr. Subodh Verma: Right. So, Greg, we actually did look at various subgroups and covariates, including gender, including age. And age or gender did not really influence the overall result that we obtained. There was really a neutral result in empagliflozin, irrespective of these 2 covariates. We also looked at baseline blood pressure, baseline NT-proBNP, LV mass indices, the presence or absence of heart failure, chronic kidney disease. So for the covariates that we have evaluated over a short term of 6 months in this relatively low risk population, we did not find any heterogeneity the result, per se. Dr. Greg Hundley: Very good. Well, Subodh, thank you so much for that beautiful presentation. And listeners, now we're going to turn to our guest editor, Dr. Chris Granger. And Chris is an expert in the field of heart failure. Also, a lot of familiarity with HFpEF, which sounds a little bit, we're looking at precursors. We don't have HFpEF yet, but maybe trying to inhibit this from happening using empagliflozin. How do you put these results in the context with other studies that have emphasized utilizing SGLT2 inhibitors in patients with sort of a preserved ejection fraction and absence of diabetes? Dr. Christopher Granger: Yeah. Well thanks, Greg. And again, congratulations, Subodh, to your study. And I think you framed some of the context here as these drugs, the SGLT2 inhibitors, as being transformative, which I think is exactly right. And it's such a fascinating story. Right? These drugs, which we thought originally, with their cause of glucose spilling in the urine, and a modest decrease in blood glucose, might have a role for modestly improving glucose control in diabetes. And low and behold, they've turned out to be one of the great stories I think in recent, across all of medicine, in terms of their consistent and substantial improving clinical outcomes for patients with heart failure, with diabetes and cardiovascular disease, and now even kidney protection, and much broader implications. And their well tolerated, and they don't have dose titration. So there's some practical appeal to this class of drugs in terms of their benefits, in terms of clinical outcomes. But we're left with having this amazing evidence-based generated without really understanding why are these drugs so effective? And what are they doing? And you've provided, I think, an important piece to the puzzle. We did have the data from patients with diabetes and heart failure, with diabetes and left ventricular hypertrophy, that there is a modest reduce in LV mass with SGLT2 inhibitors. And what you've shown is that for patients that with mild LVH, with risk for LVH, that we simply don't see a substantial reduction in LV mass with the use of these drugs. So I think that provides this evidence that that's not a major cause of benefit, at least in this earlier phase of development of heart failure. And I think it really underscores the fact that there's a lot of work to do still to understand. We know that the renal effects are obvious place that these drugs have such an important benefit. And then the linkage of renal disease and cardiac performance is one of the areas, I think, that's a very exciting aspect of a probable contribution of the mechanism of these drugs. But I think in the end, we're left with still not really understanding why these drugs are so beneficial. But understanding that, I think, will be important, both for opening new avenues of targeting pathways, as well as being able to tell the clinical community, okay, you have these important benefits, but people do want to also know why are we seeing these benefits. Dr. Greg Hundley: Very nice. Well, listeners, we're going to turn back to Dr. Verma here. Subodh, what do you see is the next study to be performed in this sphere of research? Dr. Subodh Verma: Well, first, my thanks to Professor Granger, Chris, for handling this paper and for his very thoughtful comments. And he's absolutely right. We have such wonderful clinical data, and these results, of course, should not in any way take away from the importance of using empagliflozin or other SGLT2 inhibitors in the prevention of heart failure in people with diabetes, or in the treatment of HFpEF or HFrEF. But we're struggling with trying to understand what is the dominant mechanism of action here. And, in the previous precursor to EMPA-HEART 2, we did EMPA-HEART 1 in people with diabetes, and we saw a modest effect that was statistically significant of reduction in LV mass index. And we did not see this, of course, in a lower risk population without diabetes. And that tells me that remodeling may be occurring to a modest effect, it may require a longer time to actually show its benefits, but that this is unlikely a dominant sort of mechanism through which these drugs are working. And I do share Chris's thoughts that one of the key mechanisms of benefit that needs to be further explored is looking at the renal cardiac axes. We know that these drugs are profoundly renal protective, and that the benefits may actually be secondary to improvements in renal hemodynamics, improvements in renal function. And I think that is a population that needs to be, that's a mechanism that needs to be studied further. So I think the next generation of translational mechanistic studies need to really tease out the renal cardiac axes, maybe tease out populations that are at risk but have more significant left ventricular hypertrophy, maybe evaluate patients for a longer duration of treatment, or select people who truly have significant hypertension at baseline. I think those are groups and questions that need further exploration. And, of course, the translational science needs to be also studied in the context of larger completed clinical trials, where biomarkers are currently available and they can be linked, of course, to the outcomes in those trials. So those are some of my thoughts as to where the field could move towards. Dr. Greg Hundley: Very nice. And Chris, do you have anything to add? Dr. Christopher Granger: Subodh, I think that was a great summary. And I might just make a comment on the other end of the spectrum. That is, we have these drugs and the evidence of their benefit, and yet they're grossly underused in the populations that have proven to have benefit. Now it takes some time to educate, to get people familiar with, and get them to integrate these treatments into practice, but there's an enormous opportunity, and I think there is a linkage here. I think when people understand the mechanism, and when they're thoughtful about how these drugs may be working, that that really helps to make the case that the drug should be used, and that people are on board with using them. So I think there's this linkage here, there's the need to both better understand mechanism, and there's the need to have systems of care where these treatments are integrated to provide the benefit that's been so clearly shown in the randomized trials. Dr. Greg Hundley: Very nice. Well, listeners, we want to thank Dr. Subodh Verma, from St. Michael's University in Toronto, and our guest editor, Dr. Chris Granger, from Duke University in Durham, North Carolina, for bringing this paper highlighting that among people with neither diabetes nor significant heart failure but with risk factors for adverse cardiac remodeling, that SGLT2 inhibition with empagliflozin did not, did not, result in a meaningful reduction in LV mass index after 6 months. Well, on behalf of Carolyn, Peder, and myself, we want to wish you a great week, and we will catch you next week on the run. This program is copyright of the American Heart Association 2023. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

VIDEOS: The fight for water | DW Documentary   New study shows Rhodiola rosea root might be beneficial for managing type 2 diabetes University of California at Irvine, August 15, 2022 A team of researchers led by the University of California, Irvine has discovered that treatment with an extract from the roots of the Rhodiola rosea plant might be effective for helping manage type 2 diabetes, showing promise as a safe and effective non-pharmaceutical alternative. The study, recently published online in Scientific Reports, found that in a mouse model of human type 2 diabetes, Rhodiola rosea lowered fasting blood sugar levels, improved response to insulin injections, modulated the composition of bacteria in the gastrointestinal tract and decreased several biomarkers of inflammation. The team utilized a genetically engineered mouse model that develops obesity, insulin resistance and high blood sugar, similar to advanced human type 2 diabetes, to test whether Rhodiola rosea could improve glucose homeostasis. In the study, cohorts of age-matched male and female mice were randomly assigned to one of two groups: control, which received water, or experimental, which received Rhodiola rosea extract. (NEXT) Meta-analysis concludes benefits for selenium supplementation in cognitively impaired individuals Instituto de Pesquisa Pelé Pequeno Príncipe (Brazil), August 15 2022.  A systematic review and meta-analysis published  in Nutrients found that supplementing with selenium was associated with improved levels of the mineral and the antioxidant enzyme glutathione peroxidase, as well as better cognitive function among patients with mild cognitive impairment (MCI) or Alzheimer disease (AD).  “For the first time, our study demonstrated, through a systematic review and meta-analysis, the possible benefits of selenium supplementation on selenium levels in patients with MCI or AD, as well as on markers of oxidative stress and on cognitive test performance,” Meire Ellen Pereira and colleagues wrote. Among studies that evaluated the effects of selenium without other nutrients, selenium measured in plasma, serum, red blood cells or cerebrospinal fluid increased among participants who received the mineral while remaining essentially the same or lower in the control groups. The meta-analysis determined that supplementing with selenium increased selenium levels by an average of 4 times in plasma, 1.88 times in serum, 3.73 times in red blood cells and 2.18 times in cerebrospinal fluid.  (NEXT) Skip the elevator: A 15-minute walk can help your brain fight off Alzheimer's German Center for Neurodegenerative Disease, August 15 2022 Older people can stave off Alzheimer's disease with a daily 15-minute walk or other physical activities, according to new research. Researchers in Germany say moderate physical activity boosts all areas of the brain, especially those involved in memory. Staying active also benefits people over 70 the most. They see the biggest increase in grey matter, compared to their “couch potato” peers. “Our study results indicate that even small behavioral changes, such as walking 15 minutes a day or taking the stairs instead of the elevator, may have a substantial positive effect on the brain and potentially counteract age-related loss of brain matter and the development of neurodegenerative diseases. In particular, older adults can already profit from modest increases of low intensity physical activity.” (NEXT) Antioxidants in fruit boosts immunity and protects thymus gland  Scripps Research Institute, August 8, 2022 Eating fruit and vegetables or taking antioxidant supplements may combat one of the most harmful aspects of aging by protecting a vital immune system organ, research suggests. Scientists demonstrated how ageing sabotaged the thymus gland, weakening the immune system and putting the elderly at greater risk of infection. But the irreversible damage could be reduced by the action of antioxidants such as vitamin C. Experiments showed that antioxidants – which are abundant in many fruits and vegetables – cut down the destruction wrought by a highly reactive by-product of normal metabolism. In studies on mice, animals given vitamin C and another antioxidant used in human medicine experienced significantly less age-related deterioration of the thymus. US lead scientist Dr Howard Petrie, from the Scripps Research Institute in San Diego, California, said: “The thymus ages more rapidly than any other tissue in the body, diminishing the ability of older individuals to respond to new immunologic challenges, including evolving pathogens and vaccines. Its function is to manufacture T-cells, essential immune system cells in the front-line of the body's defences against harmful foreign invaders and cancer. (NEXT) Modern Processed Diets Are Coding DNA and Gut Bacteria To Pass On Poor Immune Functions To Our Children Yale University and Erlangen-Nuremberg University, August 6, 2022 A team of scientists from Yale University in the U.S and the University of Erlangen-Nuremberg, in Germany, has said that junk food diets could be partly to blame for the sharp increase in autoimmune diseases such as multiple sclerosis, including alopecia, asthma and eczema. The new stark warnings come in a review published in Nutrition Journal, which analysed the impact that the modern Western diet has on immune function and risk of ill-health related to poor immunity and inflammation."While today's modern diet may provide beneficial protection from micro- and macronutrient deficiencies, our over abundance of calories and the macronutrients that compose our diet may all lead to increased inflammation, reduced control of infection, increased rates of cancer, and increased risk for allergic and auto-inflammatory disease," warned Myles in his review. Each person harbors a unique and varied collection of bacteria that's the result of life history as well as their interactions with the environment, diet and medication use. Western diet and lifestyles consisting of fast and processed foods are leading to a lower diversity of bacteria in the gut, say researchers. Of potentially greatest concern, our poor dietary behaviours are encoded into both our DNA scaffolding and gut microbiome, and thus these harmful immune modifications are passed to our offspring during their most critical developmental window. (NEXT) The aging heart accumulates mutations—while losing the ability to repair them Children's Hospital Boston, August 12, 2022 Why does the risk of heart disease go up as we age? Known risk factors such as hypertension or high cholesterol don't explain all cases. A first-of-its-kind study from Boston Children's Hospital now shows that the cells that make up our heart muscle accumulate new genetic mutations over time—while losing the ability to repair them. The findings were published in the journal Nature Aging. The research team, led by Sangita Choudhury, Ph.D., and August Yue Huang, Ph.D., in the Division of Genetics and Genomics at Boston Children's, sequenced the entire genomes of 56 individual heart muscle cells, known as cardiomyocytes, from 12 people across the age spectrum—from infancy to 82 years—who had died from causes unrelated to heart disease.  

Apriremo il nostro programma discutendo di alcuni avvenimenti che hanno fatto notizia questa settimana. Inizieremo, parlando ancora una volta del conflitto tra Russia e Ucraina e cercheremo di capire come potrebbe andare a finire la guerra tra questi due paesi. Successivamente, discuteremo della dura condanna da parte di Israele nei confronti delle parole offensive sul nazismo pronunciate dal ministro degli Esteri russo Sergei Lavrov. Quindi, nella parte scientifica, parleremo del risultato di uno studio pubblicato sulla rivista Nature Aging che ha chiarito qual è la quantità ideale di sonno che un adulto dovrebbe concedersi. Infine, concluderemo la prima parte del nostro programma su una nota più leggera indagando sul motivo per il quale l'ex presidente degli Stati Uniti Donald Trump (molto seriamente) temeva di essere ucciso dal lancio di pomodori.    Passiamo ora all'annuncio della seconda parte del nostro programma, “Trending in Italy”. Ricorderemo la scomparsa della fotoreporter siciliana Letizia Battaglia, nota per aver documentato uno dei periodi più sanguinosi della lotta alla mafia e per aver raccontato il disagio sociale di Palermo, attraverso i volti di donne e bambine. Parleremo poi dell'iniziativa del comune di Braies che mira a mettere un freno al turismo di massa nei mesi più belli e più caldi dell'anno, limitando l'accesso ad un numero eccessivo di visitatori. - Come potrebbe finire la guerra in Ucraina? - La Russia paragona Zelensky a Hitler e accusa Israele di sostenere i nazisti - La ricerca conferma che 7 ore di sonno sono il tempo di riposo ideale per gli adulti - Donald Trump temeva di essere ucciso dai lanci dei pomodori - È morta Letizia Battaglia, fotoreporter che raccontò Palermo e la lotta alla mafia - Il Lago di Braies solo su prenotazione

Nous commencerons notre émission en discutant de nouvelles qui ont fait les gros titres cette semaine. Tout d'abord, nous continuerons à analyser le conflit entre la Russie et l'Ukraine. Nous tenterons de répondre à la question suivante : comment la guerre entre la Russie et l'Ukraine va-t-elle se terminer ? Ensuite, nous parlerons de la condamnation par Israël des derniers propos offensants du ministre russe des Affaires étrangères, Sergueï Lavrov, sur le nazisme. Puis, dans la partie scientifique, nous commenterons les résultats d'une étude publiée dans la revue Nature Aging qui a révélé quel est le nombre d'heures de sommeil optimal pour des adultes. Enfin, nous terminerons la première partie de notre émission sur une note plus légère en essayant de comprendre pourquoi l'ancien président américain Donald Trump a eu peur (very seriously) d'être tué par un lancer de tomates.    Continuons maintenant avec l'annonce de la deuxième partie de notre émission, « Trending in France ». Nous parlerons d'une consultation nationale en France sur les nouveaux systèmes de vidéosurveillance « intelligente » utilisés dans les supermarchés. Et pour finir, nous discuterons d'une nouvelle émission de télévision lancée cette semaine en France, qui fait revivre à l'écran des personnalités décédées. - Comment va se terminer la guerre en Ukraine ? - La Russie compare Zelensky à Hitler et accuse Israël de soutenir les nazis - Selon une étude, l'idéal pour les adultes serait de dormir 7 heures par nuit - Donald Trump craignait d'être tué par des tomates - La Cnil se penche sur les systèmes d'intelligence artificielle utilisés dans les supermarchés - Les stars décédées reviennent à l'écran dans une nouvelle émission de télé

Alimenti, digiuno, geni e longevità. Sulla rivista cell è stato appena pubblicato uno studio che definisce le caratteristiche della dieta della longevità. A Obiettivo Salute il commento di Valter Longo, Direttore dell'Istituto di Longevità della University of Southern California a Los Angeles e Direttore del programma di ricerca Oncologia & Longevità all'IFOM che ha coordinato lo studio Ogni età ha il suo sonno. Questo è quanto emerge da uno studio condotto nel Regno Unito e pubblicato su Nature Aging che ha analizzato il tempo del giusto riposo notturno dopo i 40 anni. A Obiettivo Salute il commento del prof. Lino Nobili, vice presidente dell'Associazione italiana di medicina del sonno e docente all'Università di Genova

如果你相信最新一期《自然老化》(Nature Aging) 發表的最新研究結果的話，那麼你就會記住，中老年人的最佳睡眠時間是7小時。

A new study shows that NAD levels are correlated to both your age – and your physical activity. In the study, published in the journal Nature Aging, researchers studied over 50 people: people between 20 and 30 years old, older people aged 65 to 80 with normal levels of physical activity, people 65 to 80 […] The post 135. Regular exercise boost NAD+ levels as we age appeared first on Dr. David Geier - Feel and Perform Better Than Ever.

Hoy en BDA, conversamos con Luis Somoano, propietario de uno de los dealers de autos más grandes del sur de la Florida, quien comparte los detalles que debes hacer a la hora de adquirir o cambiar tu auto.También nos acompaña el Dr. Alberto Alonso, para hablarnos sobre el estudio publicado en la revista Nature Aging que sostiene que el viagra puede ser útil en el tratamiento del Alzheimer.Y como todos los miércoles, te traemos el miércoles de inmigración, hoy con el Ab. Juan Rivera, y las ultimas noticias acerca del programa “Quédate em México” y atendiendo las inquietudes de nuestros oyentes.Finalmente, el Contacto Deportivo, con Max Andalon sobre el acontecer de la última jornada de la fase de grupos de la UEFA Champions, los amistosos de México contra Chile y los preparativos de la gran final del futbol mexicano.Y, Cesar Procel desde Houston.No olvides, si tienes comentarios, inquietudes o sugerencias, puedes contactarnos en nuestras redes sociales en Facebook @BuenosdiasAM, Instagram buenosdiasamericaam o escríbenos a Infoudradio@UNIVISION.NET

Researchers study preventing cancer and diabetes with the maqui berry NOVA Southeastern University of Florida, May 27, 2021 Aristotelia chilensis, also known as maqui berry, is a fruit-bearing shrub native to South America.  According to a study published in the journal Phytochemical Analysis, maqui berries are rich in anthocyanins, which give the fruits their dark purple color. Anthocyanins are plant pigments that possess many remarkable biological properties, such as antioxidant, anti-inflammatory, anti-viral and anti-cancer activities. In a recent study, researchers at NOVA Southeastern University in Florida discussed the potential of Chilean maqui berry for use as a nutritional supplement that can help treat hyperinsulinemia and related diseases. Hyperinsulinemia, or higher-than-normal insulin levels, is often caused by insulin resistance, which is said to be the precursor to diabetes. Chronic hyperinsulinemia also promotes cancer growth by allowing insulin to exert its oncogenic effects, which include enhancing growth factor-dependent cell proliferation, among others. The researchers discussed how Chilean maqui berry can help with insulin resistance and reduce cancer risk in an article published in the journal Food Science and Human Wellness. The medicinal benefits of Chilean maqui berry Researchers have long considered nutritional supplementation to be a possible alternative or adjunct treatment to conventional therapies for common ailments and diseases. According to recent studies, maqui berries can reduce postprandial insulin levels by as much as 50 percent and are just as effective as metformin at increasing insulin sensitivity and stabilizing blood glucose levels. Maqui berries’ mechanism of action involves inhibiting sodium-dependent glucosetransporters in the small intestine and slowing the rate of entry of glucose in the bloodstream. Thanks to these actions, maqui berries can effectively reduce the likelihood of blood sugar spikes and prevent the corresponding rise in insulin levels that follows.  At the same time, maqui berries contribute to cancer prevention since chronically high blood glucose levels — besides chronic hyperinsulinemia — are also linked to the development of cancer. In fact, numerous studies have shown that diabetics and prediabetics have an elevated risk of developing cancerous growths. Based on the findings of previous studies, the researchers believe that consistent supplementation with Chilean maqui berries could indirectly reduce the risk of cancer and other diseases that are promoted by hyperglycemia (high blood sugar) and hyperinsulinemia.     Studies reveal that social isolation and quarantine throughout the COVID-19 pandemic may have a detrimental impact on physical and mental health of people living with pre-existing conditions University of Naples (Italy) and Teva Pharmaceuticals, May 30, 2021   Abstract 803: Impact of social isolation and quarantine on the course of diabetes mellitus and its complications during Covid 19 pandemic in Adjara Region Country of Georgia Abstract 1337: Psychological distress in patients with hypocortisolism during mass quarantine for Covid-19 epidemic in Italy Studies reveal that social isolation and quarantine throughout the COVID-19 pandemic may have a detrimental impact on people living with pre-existing conditions.  Social isolation and quarantine can have a detrimental impact on physical and mental health of people living with pre-existing conditions, according to two studies being presented at the 23rd European Congress of Endocrinology (e-ECE 2021)  The studies bring together research on the impact of social isolation and quarantine for people living with diabetes in the Adjara Region of Georgia, and on patients with hypocortisolism in Italy. Both studies reported that social isolation during the pandemic caused significant psychological and/or physical distress on the observed individuals.  Data from the first study revealed that the impact of quarantine on people living with diabetes in the Adjara Region caused blood pressure (BP) levels to increase in 88.2% of patients with 50% of these cases resulting in high BP hospitalisation. In addition to these physical factors, increased feelings of anxiety and fear were observed on 82% of patients. In the second study, patients with hypocortisolism experienced increased anxiety and depression, associated with a dissatisfaction feeling of self and a reduced resiliency, when compared with Italian healthy controls. As these are all contributing factors to overall health deterioration, these findings suggest further research is required to allow patients with pre-existing conditions to remain fit and healthy during the current pandemic. In the Adjara Region study, Dr Liana Jashi and the research team disseminated an online questionnaire and collected answers from 16 endocrinologists and 22 family and general practice doctors. The study confirmed the negative, indirect effects social isolation and quarantine had on people living with diabetes. It reported a list of negative effects such as the reduced access to medical care, weight gain and increased cigarette and alcohol consumption. Physical activity decreased by 29.8%, a vital preventative to further physical and psychological problems.  "This study highlights that people living with diabetes require greater support during pandemics to maintain exercise and protect their physical and mental health. National health services should use these data and future studies to implement better social care around supporting people with pre-existing conditions," commented Dr Jashi. In the second study, Dr Chiara Simeoli at the University of Naples reported data collected during the last three weeks of the mass quarantine lasted 2 months in Italy, in a web-survey-based, multicenter, case- control research involving 12 different Italian centres. The study confirmed that a large cohort of 478 patients with hypocortisolism, and particularly, 363 with adrenal insufficiency and 115 with congenital adrenal hyperplasia, adequately treated with glucocorticoids, showed higher anxiety and depression, associated with a dissatisfaction feeling of self and a reduced resiliency, when compared with Italian healthy controls, suggesting the detrimental impact of social isolation on mental health of these patients, particularly frail and vulnerable to infections and stress. Moreover, patients with adrenal insufficiency reported a worse quality of life than patients with congenital adrenal hyperplasia.  "These findings confirmed that beyond the huge impact on physical health, COVID-19 epidemic, social isolation and mass quarantine represent significant psychological stressors, causing severe effects on mental health, even more on people with pre-existing conditions. An empowerment of psychological counselling for these vulnerable patients during COVID-19 should be considered by national health-care services," adds Dr Simeoli.  Both studies indicate that additional larger studies over a longer period of time are needed for further investigation.       Researchers discover link between local oxygen depletion in the brain and Alzheimer's disease University of Seville (Spain), May 24, 2021 The study, published in the journal Nature Aging and led by the laboratories of Dr. Alberto Pascual (CSIC), from the Neuronal Maintenance Mechanisms Group, and Prof. Javier Vitorica (University of Seville/CIBERNED) of the Physiopathology of Alzheimer's Disease Group at IBiS, demonstrates for the first time that low oxygen levels in the so-called senile plaques in the brain reduces the immune system's defensive capacity against the disease. The study also suggests that this lack of oxygen in the brain enhances the action of disorders associated with Alzheimer's disease that are characterized by low systemic oxygen levels, such as atherosclerosis and other cardiovascular diseases. What happens in the brain? A characteristic feature of Alzheimer's patients is the accumulation of highly toxic substances in their brains, known as senile plaques. The brain has an immune system whose main component are the microglial cells, which were first described and named 100 years ago by Pío del Río Hortega, a disciple of Ramón y Cajal. In the absence of damage, these cells facilitate the neurons' function. In response to Alzheimer's disease, microglia defend neurons by surrounding senile plaques, preventing their spread in the brain and decreasing damage. Alzheimer's disease is aggravated by other pathologies, such as cardiovascular diseases, which cause a decrease in oxygen levels in the body. This study has revealed reduced oxygen levels around senile plaques, compromising microglial activity (Image, center). When this is compounded by reduced oxygen supply to the brain due to other systemic pathologies, the microglia are unable to provide protection and there is an increase in the pathology associated with the disease. Relevance Alzheimer's disease is the leading cause of dementia in Spain and around the world. In Spain, its incidence is increasing dramatically as the population ages. Unfortunately, the origin of the disease remains unknown. The mechanism proposed in this study is mediated by the expression of the HIF1 molecule, whose discoverers received the Nobel Prize in Physiology or Medicine in 2019. Increased HIF1 levels compromise the mitochondrial activity of microglial cells and limit their protective capacity against disease. This study opens new lines of research to improve the metabolic capacity of microglia, which would enable a sustained response over time against the disease. Indirectly, the study supports previous work highlighting the importance of maintaining good cardiovascular health for healthy aging.   Effect of different doses of melatonin on learning and memory deficit in Alzheimer model Guilan University of Medical Sciences (Iran), May 21, 2021   According to news reporting out of Rasht, Iran, research stated, “Alzheimer Disease (AD) is an age-related neurodegenerative disorder with a progressive impairment of cognitive function. The pineal gland hormone melatonin (MEL) has been known as a protection agent against AD.” Our news reporters obtained a quote from the research from Guilan University of Medical Sciences: “However, the effect of melatonin in various doses is inconsistent. In this study, we aimed to investigate two doses of MEL on learning and memory in the amyloid-beta (Ab)-induced AD in the rats. Forty-eight male Wistar rats were used in the experiment and randomly divided control, sham, vehicle, AD, AD+MEL10 mg/kg, and AD+MEL 20 mg/kg groups. Intracerebroventricular injection of Ab1-42 was used to develop the animal model of AD. Also, MEL-treated groups received an intraperitoneal injection of MEL for 4 next weeks. The Morris Water Maze (MWM) and Passive Avoidance Learning (PAL) tests were used to examine animals’ learning and memory. The brain of animals was removed for immunohistochemistry for anti- Amyloid Precursor Protein (APP). Intra-peritoneal injection of MEL significantly improve learning and memory in MWM (P=0.000) and PAL test (P=0.000), but there were no significant changes in the two groups that received the melatonin (P>0.05). Histopathological analysis revealed that the clearance of APP deposition in the AD+MEL20 group was considerable compared with the AD+MEL10 group (P=0.000).” According to the news editors, the research concluded: “Our findings indicate that 10 and 20 mg/kg doses of melatonin have similar results on learning and memory in the AD model. But 20 mg/kg of melatonin has significantly more effect on the clearance of APP deposition.”     Effects of flaxseed on blood pressure, body mass index, and total cholesterol in hypertensive patients: A randomized clinical trial Lorestan University of Medical Sciences (Iran), May 25, 2021 Objectives Given the antioxidant properties of flaxseed and its biologically active ingredients, this study was conducted to determine the effects of flaxseed supplementation on body mass index (BMI), blood pressure, and total cholesterol levels in patients with hypertension. Methods In this triple-blind clinical trial, 112 patients, with an age range of 35 to 70 years, were randomized to 2 groups receiving 10 g (n=45) and 30 g (n=45) of flaxseed supplementation and 1 group receiving placebo (n=45) for 12 weeks by stratified block randomization. They were evaluated in terms of systolic (SBP) and diastolic blood pressure (DBP), BMI, and total serum cholesterol. Physical activity was measured using the International Physical Activity Questionnaire–Short Form (IPAQ–SF) and food intake was assessed using the Food Frequency Questionnaire (FFQ). The data were analyzed with SPSS, version 22, using the chi-square, Kruskal–Wallis, repeated measures analysis, ANOVA, and ANCOVA tests. Results The interaction effects among the study groups and time on the mean SBP (p = 0.001), DBP (p = 0.001), total cholesterol level (p = 0.032), and BMI (p < 0.001) were significant. During the study, the 30-g group achieved the best results, so that a 13.38-unit decrease in SBP was observed compared to a 1.72 unit increase in the placebo group and a 5.6-unit decrease in DBP was measured compared to a 2.39 unit increase in the placebo group. BMI decreased by 0.86 units compared to 0.06 units in the placebo group. Total cholesterol also decreased by 20.4 units compared to 11.86 units in the placebo group. Conclusion The results of this study showed that flaxseed can be effective in reducing blood pressure, total cholesterol, and body mass index in hypertensive patients in a twelve-week period.     Study: Don't count on caffeine to fight sleep deprivation Michigan State University, May 27, 2021 Rough night of sleep? Relying on caffeine to get you through the day isn't always the answer, says a new study from Michigan State University. Researchers from MSU's Sleep and Learning Lab, led by psychology associate professor Kimberly Fenn, assessed how effective caffeine was in counteracting the negative effects of sleep deprivation on cognition. As it turns out, caffeine can only get you so far. The study -- published in the most recent edition of Journal of Experimental Psychology: Learning, Memory, & Cognition -- assessed the impact of caffeine after a night of sleep deprivation. More than 275 participants were asked to complete a simple attention task as well as a more challenging "placekeeping" task that required completion of tasks in a specific order without skipping or repeating steps. Fenn's study is the first to investigate the effect of caffeine on placekeeping after a period of sleep deprivation. "We found that sleep deprivation impaired performance on both types of tasks and that having caffeine helped people successfully achieve the easier task. However, it had little effect on performance on the placekeeping task for most participants," Fenn said. She added: "Caffeine may improve the ability to stay awake and attend to a task, but it doesn't do much to prevent the sort of procedural errors that can cause things like medical mistakes and car accidents."  Insufficient sleep is pervasive in the United States, a problem that has intensified during the pandemic, Fenn said. Consistently lacking adequate sleep not only affects cognition and alters mood, but can eventually take a toll on immunity.  "Caffeine increases energy, reduces sleepiness and can even improve mood, but it absolutely does not replace a full night of sleep, Fenn said. "Although people may feel as if they can combat sleep deprivation with caffeine, their performance on higher-level tasks will likely still be impaired. This is one of the reasons why sleep deprivation can be so dangerous." Fenn said that the study has the potential to inform both theory and practice.  "If we had found that caffeine significantly reduced procedural errors under conditions of sleep deprivation, this would have broad implications for individuals who must perform high stakes procedures with insufficient sleep, like surgeons, pilots and police officers," Fenn said. "Instead, our findings underscore the importance of prioritizing sleep."     Parkinson's disease more likely in people with depression, study suggests Umea University (Sweden), May 21 2021     People with depression may be more likely to develop the movement disorder Parkinson's disease, according to new research published in Neurology.   According to the authors of the study, depression is more common in people with Parkinson's disease than those without the movement disorder. "We saw this link between depression and Parkinson's disease over a timespan of more than 2 decades, so depression may be a very early symptom of Parkinson's disease or a risk factor for the disease," says study co-author Prof. Peter Nordström, at Umeå University in Sweden. Parkinson's disease is a progressive disorder of the nervous system that affects how a person moves, including how they speak and write. As well as problems with movement, Parkinson's disease can also cause cognitive problems, neurobehavioral problems and sensory difficulties. The authors of the study state that depression is more common in patients with Parkinson's disease than in members of the general population. The mood disorder has a major influence on health-related quality of life and could also be involved in more rapid deterioration of cognitive and motor functions. However, few studies have investigated this association for periods of longer than 10 years, with any long-term findings so far inconclusive. For the study, the researchers used a cohort consisting of all Swedish citizens aged 50 years and above as of December 31st, 2005. From this group, they then took the 140,688 people diagnosed with depression . These individuals were each matched with three control participants (a total of 421,718 controls) of the same age and sex who had not been diagnosed with depression. The participants were then followed for up to 26 years. A total of 1,485 people with depression (1.1%) developed Parkinson's disease during this time, compared with 1,775 of those who did not have depression (0.4%). On average, Parkinson's disease was diagnosed 4.5 years after the beginning of the study, with the likelihood of the disorder developing decreasing over time. No sibling link found for depression and Parkinson's disease The researchers calculated that participants with depression were 3.2 times more likely than those without depression to develop Parkinson's disease within a year of the study beginning. After 15-25 years, the researchers found participants with depression were almost 50% more likely to develop the condition. If a participant's depression was severe, their likelihood of developing Parkinson's disease was also higher. For example, those who had been hospitalized for depression five or more times were 40% more likely to develop Parkinson's disease than participants who had been hospitalized for depression just once. In addition to these observations, the researchers examined siblings. No link was found between one sibling having Parkinson's disease and the other having depression. "This finding gives us more evidence that these two diseases are linked," says Prof. Nordström. "If the diseases were independent of each other but caused by the same genetic or early environmental factors, then we would expect to see the two diseases group together in siblings, but that didn't happen." The authors suggest there are a number of mechanisms that could explain their findings. Depression or antidepressive treatment could increase the risk of Parkinson's disease, depression could be an early symptom of Parkinson's disease, or that the two conditions could share environmental causative factors. In the paper, the authors acknowledge that they are unable to evaluate the potential role of substances used in antidepressive treatment as risk factors for Parkinson's disease. The study is an observational one and cannot determine causation. "Our findings suggest a direct association between depression and subsequent [Parkinson's disease], supported by a time-dependent hazard ratio, a dose-response pattern for recurrent depression, and a lack of evidence for coaggregation among siblings," the authors conclude. "Given that the association was significant over more than two decades of follow-up, depression may be a very early prodromal symptom of or a causal risk factor for [Parkinson's disease]." Elsewhere, a study published in December previously suggested that users of methamphetamine are at three times more risk of getting Parkinson's disease than people who do not use illegal drugs.

Un gruppo di ricercatori della Duke University, in uno studio pubblicato sulla rivista Nature Aging, ha sottolineato come la mezza età, ovvero i 45 anni, sia il momento giusto per sottoporsi a un controllo generale e capire se si sta invecchiando bene, benino o maluccio. E di invecchiamento parliamo a Obiettivo Salute risveglio con il prof. Giovanni Scapagnini, Ordinario di Nutrizione Umana all’Università degli Studi del Molise e vicepresidente SINUT Società Italiana Nutraceutica

Host Kevin Patton outlines several new discoveries, including the function of background noise in the brain, how exercise triggers immunity, a possible blood marker for longevity, and how mitochondria are organized during cell division. And he discusses how easy animation effects can help students focus on important elements of the story of anatomy and physiology. 00:00 | Quotation & Intro 00:47 | Brain's Background Noise 08:06 | Sponsored by AAA 09:12 | How Exercise Triggers Immunity 13:30 | Sponsored by HAPI 14:41 | Mitochondria During Cell Division 22:10 | Sponsored by HAPS 23:03 | How Old Will We Get 26:22 | Focus Our Story on Slides 35:22 | The Scoop About Segments 36:33 | Smooth Slides for a Smooth Story 43:56 | Staying Connected If you cannot see or activate the audio player click here. Apply for your credential (badge/certificate) for listening to this episode. Please take the anonymous survey: theAPprofessor.org/survey Questions & Feedback: 1-833-LION-DEN (1-833-546-6336) Follow The A&P Professor on Twitter, Facebook, Blogger, Nuzzel, Tumblr, or Instagram! We deal with our mind from morning till evening, and it can be our best friend or our worst enemy. (Mathieu Ricard)   Brain's Background Noise 7 minutes The so-called "background noise" in an electroencephalogram (EEG)—that aperiodic data that contrasts with the periodic waves we usually look for—may be a measure of consciousness. Brain's ‘Background Noise' May Hold Clues to Persistent Mysteries (Quanta magazine article) my-ap.us/3lisLqW Most brain activity is "background noise" — and that's upending our understanding of consciousness (Salon magazine article) my-ap.us/30KWq2q   Sponsored by AAA 1 minute A searchable transcript for this episode, as well as the captioned audiogram of this episode, are sponsored by the American Association for Anatomy (AAA) at anatomy.org. Searchable transcript Captioned audiogram  Don't forget—HAPS members get a deep discount on AAA membership! Sign up for the new VDD or Virtual Dissection Database. You can access it at www.virtualdissectiondatabase.com   How Exercise Triggers Immunity 4 minutes We know that exercise has many beneficial effects in the body, including stimulation of the immune system. A new discovery in mice suggests that the same pressure that triggers bone growth with exercise also triggers the precursors to lymphocytes in bone marrow. Exercise generates immune cells in bone (article in Nature) my-ap.us/30JA4i5   Sponsored by HAPI Online Graduate Program 1 minute The Master of Science in Human Anatomy & Physiology Instruction—the MS-HAPI—is a graduate program for A&P teachers, especially for those who already have a graduate/professional degree. A combination of science courses (enough to qualify you to teach at the college level) and courses in contemporary instructional practice, this program helps you be your best in both on-campus and remote teaching. Kevin Patton is a faculty member in this program. Check it out! nycc.edu/hapi   Mitochondria During Cell Division 7.5 minutes We know how the nuclear genome is organized into two equivalent groups during cell division—at least the broad strokes. A new discovery sheds light on complex mechanisms that distribute the mitochondrial genome. Actin cables and comet tails organize mitochondrial networks in mitosis (article in Nature) my-ap.us/30J7cX4   Sponsored by HAPS 1 minute The Human Anatomy & Physiology Society (HAPS) is a sponsor of this podcast.  You can help appreciate their support by clicking the link below and checking out the many resources and benefits found there. Watch for virtual town hall meetings and upcoming regional meetings! Anatomy & Physiology Society theAPprofessor.org/haps   How Old Will We Get? 3 minutes A study of 90- to 100-year-olds suggests that there's a blood marker that might give clues to our longevity. More than 100 centenarians help to reveal a biomarker for long life (news item in Nature) my-ap.us/2NlN8a9 A neuronal blood marker is associated with mortality in old age (article in Nature Aging) my-ap.us/30Kxngf   Focus our Story on Slides 9 minutes It's best to have few, if any, phrases of text on our teaching slides—so that students will focus on our orally presented story of anatomy and physiology. But when we do need more than a phrase or two—a term or two—then using simple animations to bring them in one at a time works well. Slides Serve the Story of Anatomy & Physiology | Episode 66 PowerPoint: Animating Text and Objects (video) my-ap.us/30NBeZW   The Scoop About Segments 1 minute Chunking. I use segments to divide the episode partly to give room for sponsor messages (thank you, sponsors!), but also to chunk the content so that it doesn't feel like you are drinking from a fire house. You know?... a bit of a cognitive "breather" before moving on to the next thing. How to use chapter markers in Apple's Podcasts app (a how-to for flipping from segment to segment; also works similarly in other podcast platforms) my-ap.us/3bVFoVZ   Smooth Slides for a Smooth Story 7.5 minutes Smooth and subtle animations for bringing in new slide elements work better that jarring "appear" animations or wildly sliding or jumping or scrolling animations. This is especially important when considering accessibility for those with motion-sensitive conditions. Smooth... that should be our mantra! The Golden Voice Behind All Those Ken Burns Documentaries (about Peter Coyote, mentioned in this episode) https://my-ap.us/3tranz1   If the hyperlinks here are not active, go to TAPPradio.org to find the episode page. More details at the episode page. Transcript available in the transcript box. Listen to any episode on your Alexa device. Need help accessing resources locked behind a paywall? Check out this advice from Episode 32 to get what you need! https://youtu.be/JU_l76JGwVw?t=440   Take The A&P Professor experience to the next level!  The A&P Professor community   Earn cash by referring other A&P faculty to this podcast:  theAPprofessor.org/refer   Tools & Resources Amazon Text Expander Rev.com Snagit & Camtasia Krisp Free Noise-Cancelling App The A&P Professor Logo Items   Sponsors Transcript and captions for this episode are supported by the American Association for Anatomy | anatomy.org The Human Anatomy & Physiology Society provides marketing support for this podcast | theAPprofessor.org/haps Distribution of this episode is supported by NYCC's online graduate program in Human Anatomy & Physiology Instruction (HAPI) | nycc.edu/hapi Clicking on sponsor links helps let them know you appreciate their support of this podcast! Follow The A&P Professor on  Twitter, Facebook, Blogger, Nuzzel, Tumblr, or Instagram! The A&P Professor® and Lion Den® are registered trademarks of Lion Den Inc. (Kevin Patton) As an Amazon Associate I earn from qualifying purchases. I may be compensated for links to sponsors and certain other links.